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RESUMO 
As proteínas da matriz peroxissomal sintetizadas de novo são reconhecidas, no 
citosol, pelos receptores PEX5 ou PEX5.PEX7. O complexo receptor-proteína matricial 
interage com a membrana do peroxissoma e insere-se a nível do módulo de docking e 
translocação (DTM), resultando na translocação da proteína matricial para o interior do 
organelo. Após este evento, os receptores são extraídos da membrana peroxissomal em 
dois passos. Primeiro, a PEX5 é monoubiquitinada num resíduo de cisteína 
filogeneticamente conservado (Cys11 em seres humanos). Segundo, a PEX5 
monoubiquitinada (Ub-PEX5) é removida para o citosol, pelo módulo de exportação do 
receptor (REM), o que também leva à libertação da PEX7 do DTM. A extracção dos 
receptores da membrana peroxissomal é o único processo da via de importação das 
proteínas matriciais que requer a hidrólise de ATP. Uma vez no citosol, a Ub-PEX5 é 
desubiquitinada e a PEX5 solúvel pode participar num novo ciclo de transporte proteico. 
Foi recentemente proposto que a PEX5 actua também como uma holdase, evitando 
interacções prematuras ou inespecíficas, das proteínas destinadas à matriz peroxissomal, 
no citosol. Neste trabalho, foi explorada esta função da PEX5. O domínio N-terminal da 
PEX5 preveniu a agregação da malato desidrogenase, bem como a inactivação da citrato 
sintase, induzidas pela temperatura, sugerindo que a PEX5 consegue actuar como uma 
holdase. 
Uma propriedade interessante dos peroxissomas é a sua capacidade de importar 
proteínas oligoméricas. Isto revela que a maquinaria de importação das proteínas da matriz 
peroxissomal (PIM) consegue aceitar como substrato proteínas já detentoras de uma 
estrutura terciária. Uma das questões mais importantes relativas à PIM é de que forma é 
que isto acontece. Neste trabalho, foi utilizado um sistema de importação in vitro e diversas 
versões truncadas da PEX5, com o intuito de caracterizar a arquitectura do DTM. 
Descobrimos que o DTM consegue acomodar mais moléculas de uma versão truncada da 
PEX5 contendo os primeiros 197 aminoácidos (PEX5(1-197)) do que moléculas de PEX5 
full-length. Uma versão truncada da PEX5 ainda mais curta (PEX5(1-125)) é também capaz 
de interagir correctamente com o DTM, no entanto, esta molécula permanece acessível à 
proteinase K adicionada do lado citosólico, sugerindo que a protease consegue aceder ao 
DTM quando este está ocupado por uma pequena molécula de PEX5. Curiosamente, a 
interacção PEX5(1-125)-DTM é inibida por uma PEX5 truncada contendo os resíduos 138 a 
639. Aparentemente, o DTM consegue recrutar a PEX5 solúvel através de interacções com 
diferentes domínios da PEX5, sugerindo que as interacções entre o DTM e a PEX5 são, em 
certa medida, fuzzy. Finalmente, mostrámos que a interacção entre a PEX5 e a PEX14, um 
componente maioritário do DTM, é estável a pH 11.5. Assim, não é necessário assumir que 
 viii 
 
a resistência à extracção alcalina da PEX5 associada ao peroxissoma reflecte um contacto 
directo da PEX5 com os lípidos presentes na membrana. No seu conjunto, os resultados 
sugerem que o DTM é um complexo proteico que forma uma grande cavidade, na qual a 
PEX5 citosólica entra para entregar as proteínas da matriz peroxissomal. 
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ABSTRACT 
Newly synthesized peroxisomal matrix proteins are recognized in the cytosol by the 
shuttling receptors PEX5 or PEX5.PEX7. The receptor-cargo complex then docks and inserts 
into the peroxisomal membrane at the docking/translocation module (DTM), resulting in the 
translocation of the cargo protein into the organelle matrix. Following this event, the shuttling 
receptors are extracted from the peroxisomal membrane in two steps. First, DTM-embedded 
PEX5 is monoubiquitinated at a strictly conserved cysteine residue (Cys11 in humans). 
Subsequently, monoubiquitinated PEX5 (Ub-PEX5) is dislocated back into the cytosol by the 
receptor export module (REM), a step that also triggers the release of PEX7 from the DTM. 
Recycling of receptors is the only process of the peroxisomal matrix protein import pathway 
that requires ATP hydrolysis. Once in the cytosol, Ub-PEX5 is deubiquitinated, and the free 
soluble PEX5 can participate in a new protein transport cycle. 
Recently, it was proposed that PEX5 acts also as a holdase-like protein, avoiding 
premature or unspecific interactions of its cargo proteins in the cytosol. In this work, this role 
of PEX5 was explored. The N-terminal half of PEX5 prevented the thermal-induced 
aggregation of malate dehydrogenase and inactivation of citrate synthase, suggesting that 
PEX5 can act as a holdase-like protein. 
An interesting property of peroxisomes is their ability to import oligomerized proteins, 
indicating that the peroxisomal matrix protein import machinery (PIM) can accept already 
folded proteins as substrates. One of the most important questions about the PIM is how this 
happens. In this work, an established cell-free organelle-based in vitro system and several 
truncated versions of PEX5 were used to probe the DTM architecture. We found that the 
DTM can accommodate a larger number of truncated PEX5 molecules comprising amino 
acid residues 1-197 than full-length PEX5 molecules. A shorter PEX5 version (PEX5(1-125)) 
still interacted correctly with the DTM; however, this species was largely accessible to 
exogenously added proteinase K, suggesting that this protease can access the DTM when 
this is occupied by a small PEX5 protein. Interestingly, the PEX5(1-125)-DTM interaction was 
inhibited by an import-competent polypeptide comprising PEX5 residues 138-639. 
Apparently, the DTM can recruit soluble PEX5 through interactions with different PEX5 
domains suggesting that the PEX5-DTM interactions are to some degree fuzzy. Finally, we 
found that the interaction between PEX5 and PEX14, a major DTM component, is stable at 
pH 11.5. Thus, there is no reason to assume that the hitherto intriguing resistance of DTM-
bound PEX5 to alkaline extraction reflects its direct contact with the peroxisomal lipid bilayer. 
Collectively, these results suggest that the DTM is best described as a large cavity-forming 
protein assembly into which cytosolic PEX5 can enter to release its cargo. 
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1. Peroxisomes: structure and function 
Peroxisomes are present in almost all eukaryotic cells. They were first observed in 
1954 by Johannes Rhodin and named “microbodies”, a cytoplasmic body characterized by a 
single membrane and a finely granular matrix in electron microscopy (1). The designation 
“peroxisome” was introduced in 1965 by Christian de Duve to highlight their content in 
several hydrogen peroxide-producing oxidases and catalase, which dismutates the hydrogen 
peroxide to water and molecular oxygen (2, 3). In some cells, a remarkable electron-dense 
paracrystalline structure is easily detected. For example, in mouse/rat liver cells, a core of 
urate oxidase is frequently observed ((3–5); see Figure 1), and in yeast Candida boidinii a 
core of alcohol oxidase is also common (4). Unlike mitochondria and chloroplasts, 
peroxisomes are devoid of DNA (4, 6, 7). Usually, these organelles are spherical and range 
from 0.1-1 µm in diameter. They can, however, also adopt elongated tubular or short rod-
shaped forms (4, 8). In fact, peroxisome morphology, size and abundance may vary 
according to the organism, tissue, cell type and even prevailing environmental conditions 
(reviewed in (4, 9, 10)). 
 
 
Figure 1. Peroxisomes. Electron micrograph showing peroxisomes (P) from a rat liver post-nuclear supernatant. 
A crystalline core of urate oxidase is marked (). Scale bar 0.2 µm. Electron micrograph kindly taken by Prof. Dr. 
Manuel Teixeira da Silva, IBMC, Porto, Portugal. 
 
Peroxisome functions are extremely diverse. While some functions are transversal 
and common to all kingdoms, others are very specialized and only found in a few organisms 
or cell types. Highly conserved functions are the metabolism of hydrogen peroxide (H2O2) 
and the β-oxidation of fatty acids (11, 12). The H2O2 is produced as a metabolic by-product of 
many peroxisomal oxidases. Its decomposition occurs mainly via catalase, the primary 
peroxisomal antioxidant enzyme and also the classical peroxisomal marker enzyme. Besides 
catalase, peroxisomes may contain other proteins capable of removing H2O2, such as 
peroxiredoxin V (PMP20) and glutathione peroxidase (13). β-oxidation is the main pathway of 
fatty acid degradation. In yeast and plants, it seems to be an exclusively peroxisomal 
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process. In mammals, the β-oxidation of medium and long-chain fatty acids occurs mainly in 
mitochondria with only a little contribution of the peroxisomal β-oxidation system (11). 
However, this system is critical for the β-oxidation of very long-chain fatty acids (VLCFAs) 
(11, 14, 15). In higher eukaryotes, peroxisomes are also important for the α-oxidation of fatty 
acids, biosynthesis of ether phospholipids (plasmalogens), detoxification of glyoxylate and 
synthesis of bile acids (11, 12, 14, 15). Some peroxisomes found in specific groups of 
organisms or tissues are so different and specialized that they were initially classified as 
distinct organelles and have alternative names. Peroxisomes from trypanosomatids of the 
genera Trypanosoma and Leishmania have the particularity of generally lacking catalase and 
are designated glycosomes since they contain most of the glycolytic enzymes (16, 17). 
Germinating fatty seedlings from higher plants have glyoxysomes, specialized peroxisomes 
that contain β-oxidation enzymes but also key enzymes of the glyoxylate cycle. The 
combined action of these enzymes allows glyoxysomes to convert the seed storage lipids 
into sugar, needed for seed germination and growth (18). 
 
 
2. Peroxisome disorders 
Peroxisomes are essential for human health and development. Their relevance is 
highlighted by the existence of a group of genetic diseases, the peroxisomal disorders, in 
which there is an impairment of peroxisomal function. Peroxisomal disorders are usually 
classified into two major groups: i) the peroxisomal single enzyme deficiencies, and ii) the 
peroxisome biogenesis disorders (19). 
 
2.1. Peroxisomal single enzyme deficiencies 
Peroxisomal single enzyme deficiencies are subdivided according to which specific 
peroxisomal function is compromised, namely: i) fatty acid β-oxidation, ii) fatty acid α-
oxidation, iii) ether phospholipid (plasmalogen) biosynthesis, iv) glyoxylate detoxification, v) 
H2O2 metabolism, or vi) bile acid synthesis ((15, 19, 20); see Table 1). 
The most common of these diseases is X-linked adrenoleukodystrophy (X-ALD), with 
an estimated incidence of 1:20000 to 1:30000 (21). X-ALD is caused by mutations in the 
ABCD1 gene that encodes a peroxisomal transmembrane protein, the adrenoleukodystrophy 
protein (ALDP), needed for the β-oxidation of VLCFAs. ALDP deficiency results in the 
accumulation of VLCFAs in all tissues and leads to a progressive disease characterized by 
chronic myelopathy and peripheral neuropathy (22). 
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Table 1. The peroxisomal single enzyme deficiencies. 
Peroxisomal function impaired Peroxisomal disorder 
Defective 
protein  
Fatty acid β-oxidation 
X-linked adrenoleukodystrophy ALDP/ABCD1 
Acyl-CoA oxidase deficiency ACOX1 
D-Bifunctional protein deficiency DBP 
Sterol carrier protein x deficiency SCPx 
2-Methylacyl-CoA racemase deficiency AMACR 
Fatty acid α-oxidation Refsum disease PHYH 
Ether phospholipid biosynthesis 
Rhizomelic chondrodysplasia punctata type 2 DHAPAT 
Rhizomelic chondrodysplasia punctata type 3  ADHAPS 
Rhizomelic chondrodysplasia punctata type 4 FAR1 
Glyoxylate detoxification Primary hyperoxaluria type 1  AGT 
H2O2 metabolism Acatalasemia Catalase 
Bile acid synthesis 
Bile acid-CoA: amino acid N-acyltransferase deficiency BAAT 
Acyl-CoA oxidase 2 deficiency ACOX2 
ABCD3 (PMP70) deficiency PMP70/ABCD3 
Adapted from (23, 24). Abbreviations used: ALDP, adrenoleukodystrophy protein; ACOX1, acyl-CoA oxidase 1; 
DBP, D-bifunctional protein; SCPx, sterol carrier protein x; AMACR, 2-methylacyl-CoA racemase; PHYH, 
phytanoyl-CoA hydroxylase; DHAPAT, dihydroxyacetone phosphate acyltransferase; ADHAPS, alkyl 
dihydroxyacetone phosphate synthase; FAR1, fatty acyl-CoA reductase 1; AGT, alanine:glyoxylate 
aminotransferase; BAAT: Bile acid-CoA: amino acid N-acyltransferase; ACOX2, acyl-CoA oxidase 2; PMP70, 70-
kDa peroxisomal membrane protein. 
 
2.2. Peroxisome biogenesis disorders 
Peroxisome biogenesis disorders (PBDs) are mainly caused by mutations in PEX 
genes, which encode peroxins, proteins involved in the biogenesis and maintenance of 
peroxisomes (19). Contrary to single enzyme deficiencies, in which one specific peroxisomal 
function is affected, in PBDs, several or all peroxisomal functions can be affected, and, in 
some cases, peroxisomes can be completely absent (19, 25). 
The PBDs group includes Zellweger syndrome (ZS), neonatal adrenoleukodystrophy 
(NALD), infantile Refsum disease (IRD), Heimler syndrome (HS) (these four conditions 
belong to the so-called Zellweger spectrum disorders (ZSDs)), rhizomelic chondrodysplasia 
punctata (RCDP) type1 and type 5, and peroxisomal fission defects (19, 25, 26). 
ZS is the most severe of the PBDs, being a fatal cerebro-hepato-renal syndrome. ZS 
patients are newborns with severe hypotonia, distinct craniofacial dimorphism, profound 
neurological abnormalities such as neuronal migration defects, hepatomegaly and renal 
cysts, and usually die before one year of age (19, 25). ZS is characterized by the absence of 
functional peroxisomes in cells and subsequent accumulation of peroxisomal substrates such 
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as VLCFAs, bile acid intermediates and phytanic acid in the plasma (25, 27, 28). NALD and 
IRD are less severe disorders resulting in a longer life span. NALD patients usually live until 
late infancy; they have hypotonia, seizures and progressive white matter disease. In patients 
with IRD, survival until adulthood is possible. IRD patients typically have retinopathy, hearing 
loss and psychomotor delay but do not show disordered neuronal migration or progressive 
white matter disease (19, 25). HS is the mildest PBD, with patients presenting hearing loss, 
abnormalities in teeth and nails, and sometimes retinal pigmentation. HS is characterized by 
a slight peroxisomal dysfunction (26). 
RCDP type 1 is clinically distinguished from Zellweger spectrum disorders by 
prominent skeletal manifestations. RCDP type 1 patients have symmetrical shortening of the 
limbs (i.e., rhizomelia), periarticular calcifications, cataracts, severe growth and mental 
deficiency, and, in the most severe cases, usually do not survive the first decade of life (19, 
25). RCDP type 5 was recently described in four patients from two families. The phenotype 
of RCDP type 5 may include cataracts, postnatal growth delay, microcephaly, severe 
intellectual disability and chondrodysplasia punctata (29). In RCDP type 1 and type 5 
disorders, only the function of a smaller subset of peroxisomal proteins (those containing a 
peroxisomal targeting signal type 2, see below) is compromised (29–32). RCDP type 1 and 
type 5 are characterized by the accumulation of phytanic acid, but not VLCFAs, in plasma 
from patients (29, 33). 
Peroxisomal fission defects were reported in a very small number of patients, one of 
them presenting ZSD-like symptoms but, strikingly, normal biochemical peroxisomal 
parameters (19) (see below). 
Whereas RCDP type 1 and type 5 are caused by mutations in PEX7 and very specific 
mutations in PEX5, respectively (29–32), Zellweger spectrum disorders are caused by 
mutations in any of different PEX genes, including PEX 1, 2, 3, 5, 6, 10, 12, 13, 14, 16, 19 
and 26 ((19, 25, 26); see Table 2). Defects in most of them result in peroxisomal vesicles 
containing peroxisomal membrane proteins but devoid of matrix proteins, the so-called 
peroxisomal membrane ghosts, reflecting that the encoded peroxins are involved in the 
import of peroxisomal matrix proteins (34, 35). Defects in PEX3, PEX16 or PEX19, however, 
result in the complete absence of peroxisomal vesicles, implying that the encoded peroxins 
are essential for the peroxisomal membrane biogenesis (36–40). 
Peroxisomal fission defects are associated with mutations in PEX11β, DLP1, Mff or 
GDAP1 genes. While a mutation in PEX11β results in elongated peroxisomes (41), a 
mutation in DLP1, Mff or GDAP1 results in cells with elongated or tubular peroxisomes and 
mitochondria (19). Proteins encoded by the three latter genes are required for the division of 
both peroxisomes and mitochondria, and so, for this reason they are not classified as 
peroxins. 
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Table 2. Peroxisome biogenesis disorders – correlation between mutated PEX gene, peroxisomal 
disorders and pathway affected. 
PEX gene 
mutated 
Peroxisomal disorder Pathway affected 
PEX1 ZSDs Import of matrix proteins 
PEX2 ZSDs Import of matrix proteins 
PEX3 ZSDs Import of membrane proteins 
PEX5 ZSDs, RCDP type 5 Import of matrix proteins 
PEX6 ZSDs Import of matrix proteins 
PEX7 RCDP type 1 Import of PTS2 matrix proteins 
PEX10 ZSDs Import of matrix proteins 
PEX11β Peroxisomal fission defect Proliferation of peroxisomes 
PEX12 ZSDs Import of matrix proteins 
PEX13 ZSDs Import of matrix proteins 
PEX14 ZSDs Import of matrix proteins 
PEX16 ZSDs Import of membrane proteins 
PEX19 ZSDs Import of membrane proteins 
PEX26 ZSDs Import of matrix proteins 
Adapted from (25). Abbreviations used: ZSDs, Zellweger spectrum disorders; RCDP, rhizomelic chondrodysplasia 
punctate; PTS2, peroxisomal targeting signal type 2. 
 
 
3. Peroxisome biogenesis 
Peroxisome biogenesis requires the concerted action of many proteins, most of 
which, but not all, are peroxins. To date, 35 peroxins have been identified among the several 
studied organisms (42–46). In mammals, however, only sixteen have been reported ((47); 
see Table 3). This discrepancy might suggest that there are mammalian peroxins with highly 
divergent sequences that were not identified yet by homology searching in databases. 
However, this is probably not the case. For instance, in Saccharomyces cerevisiae, due to an 
ancient whole-genome duplication event, several pairs of PEX genes performing the same or 
similar function are present. This is the case of PEX18 and PEX21, and PEX5 and PEX9 (42, 
48). This large redundancy is not found in mammals. Furthermore, some orthologue peroxins 
have received different names for historical reasons because their functional/structural 
homology was not perceived when they were first identified. For instance, PEX18 and PEX21 
from S. cerevisiae are actually equivalent to PEX20 from other yeasts and filamentous fungi. 
Additionally, the function of some peroxins not present in mammals was actually transferred 
to other peroxins or even to non-peroxin proteins. This is the case of PEX18, PEX21 and 
PEX20 from lower eukaryotes, the function of which is performed by PEX5 in higher 
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eukaryotes, or the situation for yeast and plant ubiquitin-conjugating enzyme (E2), PEX4, 
and its membrane anchor, PEX22, the function of which is carried out by mammalian 
E2D1/2/3, three multipurpose E2 enzymes involved in a myriad of other biological pathways 
(see below). Thus, it is likely that all, or almost all, genes encoding components of the 
mammalian peroxisomal matrix protein import machinery (PIM) were already identified. If so, 
then we can conclude that evolution led to simpler peroxisome biogenesis machineries (42, 
44). Importantly, despite the large species-specific differences, the mechanistic features of 
peroxisomal biogenesis have been conserved throughout evolution. 
Peroxins are usually divided into three groups, according to their roles in peroxisome 
biogenesis: i) assembly of the peroxisomal membrane, ii) import of matrix proteins into the 
organelle, and iii) peroxisome proliferation ((47); see Table 3). 
 
Table 3. Localization, properties and functions of mammalian peroxins. 
Pathway Peroxin Localization Properties / Functions 
    
Import of 
membrane proteins 
PEX3 Perox Intrinsic PMP 
PEX16 Perox Intrinsic PMP 
PEX19 Cyt/Perox Farnesylation motif; PMP receptor 
    
Import of matrix 
proteins 
PEX1 Perox Peripheral PMP, AAA ATPase; receptor export 
PEX2 Perox Intrinsic PMP, RING Zn
2+
-binding domain; E3 
PEX5 Cyt/Perox IDD, TPRs; PTS1 and PTS2 receptor 
PEX6 Perox Peripheral PMP, AAA ATPase; receptor export 
PEX7 Cyt/Perox WD-repeats; PTS2 adaptor receptor 
PEX10 Perox Intrinsic PMP, RING Zn
2+
-binding domain; E3 
PEX12 Perox Intrinsic PMP, RING Zn
2+
-binding domain; E3 
PEX13 Perox Intrinsic PMP, SH3 domain 
PEX14 Perox Intrinsic PMP, Coiled-coil domain 
PEX26 Perox Intrinsic PMP, PEX1/PEX6 membrane anchor 
    
Proliferation of 
peroxisomes 
PEX11β Perox Intrinsic PMP 
PEX11α Perox Intrinsic PMP 
PEX11γ Perox Intrinsic PMP 
Adapted from (25). Abbreviations used: Perox, peroxisome; PMP, peroxisomal membrane protein; Cyt, cytosol; 
AAA, ATPases associated with diverse cellular activities; RING, really interesting new gene; E3, ubiquitin ligase; 
IDD, intrinsically disordered domain; TPRs, tetratricopeptide repeats; PTS1, peroxisomal targeting signal type 1; 
PTS2, peroxisomal targeting signal type 2; WD, tryptophan-aspartate repeat; SH3, Src homology 3. 
 
Since peroxisomes do not contain DNA or ribosomes, all peroxisomal proteins are 
encoded by nuclear genes, synthesized in the cytoplasm and post-translationally transported 
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to the organelle (49–52). Peroxisomal membrane proteins and matrix proteins are sorted to 
peroxisomes by different and independent machineries, presented in sections I-3.1.1. and I-
3.2., respectively. 
 
3.1. Peroxisomal membrane biogenesis 
The origin of the peroxisomal membrane has continuously been a subject of debate in 
the field. Two different models have been proposed: the “growth and division model”, which 
proposes that mature peroxisomes divide giving rise to smaller new organelles, and the “de 
novo formation model”, which proposes that peroxisomes are a branch of the secretory 
pathway and, therefore, that their membrane derives from the endoplasmic reticulum (ER) 
(reviewed in (3, 4, 53–56)). Initial studies, based on electron microscopy, showed 
peroxisomes surrounded by the ER, and pointed to the idea that peroxisomes are formed by 
budding from the ER (3). Subsequent data indicating that peroxisomal matrix and membrane 
proteins are synthesized on free cytosolic ribosomes and post-translationally imported into 
peroxisomes, introduced the idea that peroxisomes are autonomous organelles capable of 
proliferating by growth and division of pre-existing ones (4, 49–52). However, the observation 
that in mutant cells lacking any peroxisomal vesicle (with defects in PEX3, PEX16 or PEX19 
peroxins), peroxisomes can form de novo upon introduction of the wild-type peroxin, gave 
again some momentum to the ER-derived model (36–39). This momentum was lost, 
however, a few years later when it was shown that yeast pex3 mutant cells do contain some 
membrane structures (formed independently of PEX3) possessing PEX13 and PEX14 and 
also some matrix proteins. When the PEX3 gene is reintroduced in these cells, PEX3 protein 
sorts directly to the preperoxisomal structures, which then mature into normal peroxisomes 
(57). Thus, presently, the “growth and division” model seems more appealing to many 
researchers. But this does not mean that a consensus on this issue has been reached. Far 
from that, as illustrated, for instance, by a recent study proposing that mammalian 
peroxisomes form de novo through the fusion of mitochondrial- and ER-derived vesicles 
((58), see also (56) for a discussion of this finding). 
Regardless of the true origin for the peroxisomal membrane, it is obvious that its 
assembly requires both the incorporation of new lipids and the insertion of membrane 
proteins into the lipid bilayer. Considering that cells synthesize membrane lipids mostly in the 
ER, and that contact sites between ER and peroxisomes have been observed (59–61), it is 
reasonable to assume that peroxisomes receive most of their membrane lipids from the ER. 
 
3.1.1. Import of membrane proteins into the organelle 
In mammals, the sorting of peroxisomal membrane proteins (PMPs) to the organelle 
requires PEX19, PEX3 and PEX16 peroxins (36–40). Newly synthesized PMPs have a 
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membrane peroxisomal targeting signal (reviewed in (62)) which is recognized by soluble 
PEX19 (63, 64). PEX19 behaves as a chaperone-like protein; it interacts with the 
hydrophobic domains of PMPs and prevents their aggregation in the cytosol (64–66). 
Moreover, PEX19 functions as import receptor and transports the PMPs to the organelle (67, 
68). At the peroxisomal membrane, PEX19 interacts with the docking protein PEX3, and in 
some way, this event results in the insertion of the PMP into the lipid bilayer, without ATP 
consumption (52, 68–70). One hypothesis is that, after docking, the cytosolic PEX19-
interacting domain of PEX3 adopts a different conformation and binds membrane lipids 
causing the release of PEX19 back to the cytosol and the insertion of PMP into the 
peroxisomal membrane (71, 72). Regarding PEX16, its function in biogenesis is still unclear. 
Even though PEX16 is essential for mammalian peroxisomal membrane biogenesis, this 
peroxin is absent in yeasts with exception of Yarrowia lipolytica (73). Although many PMPs 
are sorted to the organelle through this pathway (74), PEX3 seems to be an exception. 
Indeed, in vitro and in vivo studies have shown that PEX3 inserts into the ER, and, therefore, 
some authors believe that PEX3 reaches peroxisomes via budding vesicles (75, 76). 
 
3.2. Import of matrix proteins into the organelle 
In mammals, the PIM includes 10 peroxins organized in three functional/structural 
units: 1) the shuttling receptors for newly synthesized matrix proteins destined for the 
organelle, PEX5 and PEX5.PEX7 complex (30, 77, 78); 2) the peroxisomal membrane 
docking/translocation module (DTM), comprising PEX14, PEX13 and the really interesting 
new gene (RING) finger proteins PEX2, PEX10 and PEX12 (79–81); and 3) the receptor 
export module (REM) that comprises the two AAA ATPases PEX1 and PEX6, and their 
membrane anchor PEX26 (82–84). In addition to these 10 peroxins, the mammalian PIM 
includes a few other proteins most of which are involved in ubiquitin conjugation and 
deconjugation (85, 86). 
The import of peroxisomal matrix proteins comprises five main events, namely (see 
Figure 2): 1) recognition of the cytosolic peroxisomal matrix protein (cargo protein) by the 
shuttling receptor(s); 2) docking of the receptor-cargo complex at the peroxisomal 
membrane; 3) insertion of the complex into the organelle membrane, resulting in the release 
of cargo protein into the organelle matrix; 4) monoubiquitination of DTM-embedded PEX5, 
and; 5) dislocation of monoubiquitinated PEX5 back into the cytosol, followed by its 
deubiquitination. A detailed description of each of these events is presented below. 
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Figure 2. Peroxisomal matrix protein import cycle in mammals. For simplicity, the import pathway is 
described using a PEX5-centered perspective, so PEX7 is not represented (note that during most of the stages of 
the PEX5.PEX7-mediated import pathway, PEX7 remains bound to PEX5). Cytosolic PEX5 (stage 0) recognizes 
newly synthesized peroxisomal matrix proteins – cargo proteins (CP; stage 1a). Then, the receptor-cargo complex 
docks (stage 1b), and in a cargo- and temperature-dependent event, gets inserted at the docking/translocation 
module (DTM; stage 2). The insertion of PEX5 results in the release of the cargo protein into the organelle matrix. 
DTM-embedded PEX5 is monoubiquitinated (stage 3a), recognized by the receptor export module (REM; stage 
3b), and dislocated back into the cytosol in an ATP-dependent process. Cytosolic monoubiquitinated PEX5 (stage 
4) is deubiquitinated, most likely by a combination of enzymatic (USP9X) and non-enzymatic (e.g., GSH) 
mechanisms, yielding cytosolic free PEX5 (stage 0). Diverse strategies/tools to block this pathway at different and 
specific steps (shown by red  symbol) are indicated. Abbreviations used: cyt, cytosol; mat, peroxisomal matrix; 
CP, cargo protein; DTM, docking/translocation module; Ub, ubiquitin; E1, ubiquitin-activating enzyme; E2, 
ubiquitin-conjugating enzyme; ATPγS, adenosine 5’[γ-thio]triphosphate; PPi, pyrophosphate; REM, receptor 
export module; Pi, inorganic phosphate; USP9X, ubiquitin-specific protease 9X; GSH, glutathione; TPRs, 
recombinant protein comprising only the PEX5 tetratricopeptide repeats domain; NDPEX14, recombinant protein 
comprising the soluble N-terminal domain of PEX14; T, temperature; C11S/A, PEX5 protein-mutated version with 
the conserved cysteine 11 replaced by a serine or an alanine residue, respectively; IAA, iodoacetamide; GST-Ub, 
glutathione S-transferase ubiquitin fusion protein; Ubal, ubiquitin aldehyde. Adapted from (87). 
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3.2.1. Cargo recognition by shuttling receptors 
A newly synthesized peroxisomal matrix protein must have a peroxisomal targeting 
signal (PTS) in order to be correctly targeted to the organelle. The vast majority of matrix 
proteins have a PTS type 1 (PTS1), a C-terminal tripeptide, with the sequence serine-lysine-
leucine (S-K-L) or conservative variants ((S/A/C)-(K/R/H)-(L)) (88–90). In some cases, the 
residues upstream of the tripeptide are also important for import (90–93). A small number of 
matrix proteins lack a PTS1 and have instead a PTS type 2 (PTS2). This is a degenerated 
nonapeptide with the consensus sequence R-(L/V/I/Q)-X-X-(L/V/I/H)-(L/S/G/A)-X-(H/Q)-(L/A), 
present at the N-terminus of the protein (94–96). The PTS2 is generally cleaved in the 
peroxisomal matrix of higher eukaryotes by a specific protease (Tysnd1 in mammals; (97)) 
(98), contrary to the PTS1, which is not processed upon import. 
In the cytosol, PTS1-containing proteins are recognized by the shuttling receptor 
PEX5, which specifically targets them to the peroxisome (77, 78, 99, 100). PEX5 is a 
monomeric protein with a natively unfolded N-terminal half followed by a globular C-terminal 
domain comprising seven tetratricopeptide repeats (TPRs) (see section I-3.2.3.). The TPR 
domain interacts directly with the PTS1, and this is the most important binding interface 
between PEX5 and PTS1-containing proteins (99, 101–103), although the N-terminal domain 
of PEX5 also contributes for the interaction with these cargo proteins (104–107). 
The recognition of PTS2-containing proteins is quite different and requires a protein 
complex comprising PEX5 and PEX7. PEX7 is a WD-repeat protein that interacts with the 
PTS2 (30, 108–110) and acts as an adaptor factor of PEX5 in the interaction with the PTS2-
containing proteins (111–113). PEX5 binds PEX7 and, taking into account a recent structure 
of a trimeric complex between yeast PEX7, a PTS2 protein and PEX21 (the yeast orthologue 
of mammalian/plant PEX5 in the PTS2-mediated protein import pathway) (114), as well as 
biochemical data (115, 116), it is likely that PEX5 also interacts directly with the PTS2. 
In lower eukaryotes, PEX5 is only involved in the PTS1-mediated protein import 
pathway and PTS2 proteins are transported to the organelle by a complex comprising PEX7 
and a species-specific PEX5-like protein (117, 118). These PEX5-like proteins (i.e., PEX18, 
PEX21 and PEX20), not only display similar functions but also share structure similarities 
with the N-terminal domain of mammalian PEX5 (119, 120). 
A small number of peroxisomal matrix proteins lack either PTS1 or PTS2 within their 
polypeptide chain, but, are still targeted to the peroxisomes in a PEX5-dependent manner. In 
some cases, it is possible that there are internal signals in the proteins that interact with the 
N-terminal domain of PEX5 (104). The other possibility is that these proteins are imported 
“piggy-backed” with other proteins that do have a PTS (121–123). 
The PTS receptors, PEX5 and PEX7, show a dual subcellular localization, both are 
predominantly cytosolic with a small population found associated with the peroxisome (77, 
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100, 108, 124, 125). This dual distribution is at the basis of the so-called shuttling receptor 
model. According to this concept, PEX5 and PEX7 cycle between the cytosol and the 
peroxisome, thus, delivering newly synthesized (cytosolic) cargo proteins to the organelle 
(100, 108). 
 
3.2.2. PEX5 as a holdase-like protein 
An interesting property of peroxisomes is their ability to import already oligomerized 
proteins (reviewed in (126, 127)). Even though studies supporting the import of oligomerized 
proteins are plentiful, this route may not be that frequent. Actually, many peroxisomal matrix 
proteins that are oligomeric in their native state seem to arrive at the organelle matrix still as 
monomers. The earlier experimental evidences supporting this idea come from pulse-chase 
analysis (128). It was demonstrated that rat liver catalase – a tetrameric protein in its native 
state – is synthesized in the cytosol and subsequently transferred to peroxisomes (with a 
half-time of import of 14 min), where it appears as a monomeric protein. The oligomerization 
of catalase occurred within the peroxisomes (128). Similar experiments revealed that alcohol 
oxidase from Candida boidinii – an octameric protein – remains in a monomeric state in the 
cytosol and oligomerizes only after import into peroxisomes (129, 130). Other experimental 
evidences come from in vitro import assays, where the import efficiencies of monomeric and 
oligomeric versions of the same protein were compared. The monomeric form of isocitrate 
lyase from Cucurbita pepo – a tetrameric protein – was found to be a better peroxisomal 
import substrate than the corresponding oligomeric form (131). For mouse acyl-CoA oxidase 
1 (ACOX1) – a dimeric protein – and urate oxidase (UOX) – a tetrameric protein – the same 
preference was observed. In fact, specific peroxisomal import of the oligomeric proteins was 
not detected (132). Some additional observations support the idea that peroxisomal matrix 
proteins arrive at the organelle matrix as monomers. For example, there are peroxisomal 
matrix proteins that no longer interact with the receptor PEX5 upon oligomerization because 
their PTS1 is no longer exposed; apparently, these proteins have to stay monomeric to bind 
PEX5 and thus be transported to peroxisomes (133–135). Also, at least in rat hepatocytes, 
there is enough cytosolic PEX5 to interact with all newly synthesized peroxisomal proteins 
that are en route to the organelle (107). Additionally, PEX5 binds monomeric human catalase 
and mouse ACOX1 and UOX, strongly inhibiting their oligomerization (107, 132). The latter 
two observations led to the proposal that PEX5 is a holdase-like protein that binds newly 
synthesized monomeric peroxisomal matrix proteins and prevents premature or incorrect 
interactions in the cytosol (107, 132). 
There are, however, three examples where peroxisomes seem to import oligomeric 
proteins. These are rat liver Cu/Zn superoxide dismutase 1 (121), the two isoforms of human 
lactate dehydrogenase (122) and the yeast nicotinamidase Pnc1p (123). All these proteins 
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lack either a PTS1 or a PTS2 within their polypeptide chain, and seem to reach the 
peroxisomal matrix “piggy-backed” with specific partners that do have a PTS. Importantly, 
import of these oligomers seems to be a rather low efficiency process because a large 
fraction of them is actually found in the cytosol under steady-state conditions. 
 
3.2.3. PEX5 – structural and functional relationships 
PEX5 is present in all organisms containing peroxisomes. In mammals, the PEX5 
transcript undergoes alternative splicing to produce two main PEX5 isoforms, a larger 
(PEX5L) and a smaller (PEX5S) one. These two proteins differ by 37 amino acids, which 
actually form the PEX7-binding domain. This means that only PEX5L has the ability to 
interact with PEX7 and, thus, to target PTS2-containing proteins to the peroxisomal matrix 
(111, 112, 119). In lower eukaryotes, PEX5 lacks the PEX7-binding domain and is, therefore, 
only involved in the PTS1-mediated protein import pathway (136, 137). 
PEX5 is a 70-kDa monomeric protein (138), structural and functionally divided into 
two domains, the N-terminal and C-terminal halves, respectively (see Figure 3). 
As mentioned above, the C-terminal half of PEX5 is a globular domain and comprises 
seven tetratricopeptide repeats (TPRs) involved in recognition of PTS1-containing proteins. 
TPRs 1-3 and TPRs 5-7 form two clusters separated by TPR4, a α-helix of 21 residues, that 
corresponds to a “hinge” region. The crystal structures of the C-terminal half of PEX5 in 
complex with a PTS1-containing peptide or with a functional PTS1 protein show that the two 
clusters of TPRs create a groove that is the binding site for PTS1. When the cargo protein is 
not bound to TPRs, structural changes occur with TPRs which then presents an open “snail-
like” conformation (99, 101, 102, 139). 
The N-terminal domain of PEX5 is natively unfolded (140); it includes regions of 
interaction with three other peroxins of the PIM. These are PEX7 (in mammals and plants; 
(111, 112, 119, 141)), PEX14 and PEX13. The interaction of mammalian PEX5 with PEX14 
involves multiple sites present at the N-terminal half of PEX5. There are such eight sites, 
seven of which are the so-called di-aromatic pentapeptide repeats – the WXXXF/Y motifs – 
and another which presents the sequence LVXEF (142–146). All these motifs bind 
individually to PEX14 with high affinity (dissociation constants in the low nanomolar range) 
(142, 146). PEX5 binds mainly to the conserved N-terminal domain of PEX14 (143). The 
interaction of mammalian PEX5 with PEX13 also involves the WXXXF/Y motifs. Specifically, 
motifs 2 to 4 were implicated in PEX5 binding to the N-terminal domain of PEX13 (145). 
Additionally, PEX5 also interacts with the Src homology 3 (SH3) domain present at the C-
terminal region of PEX13 (138). In addition to these pentapeptide repeats, the N-terminal 
domain of PEX5 contains a strictly conserved cysteine residue near its N-terminus (Cys11 in 
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humans). As described later (see section I-3.2.5.), this cysteine residue is transiently 
monoubiquitinated during import of peroxisomal matrix proteins (147, 148). 
While the C-terminal half of PEX5 is highly conserved among species, the N-terminal 
half is poorly conserved, with the exception of di-aromatic pentapeptide repeats and cysteine 
residue referred to above (101, 112, 143, 149). 
 
 
Figure 3. Structure and functional components of mammalian PEX5. The large isoform of mammalian PEX5 
is schematically represented. The conserved cysteine residue at position 11 (Cys11) is marked; purple bars 
indicate the pentapeptides motifs (LVXEF (0) and WXXXF/Y (1-7)) responsible for the interaction with PEX14 and 
PEX13; the yellow box indicates the PEX7-binding domain, only present in PEX5L (absent in PEX5S); the green 
box represents the seven tetratricopeptide repeats (TPRs), the PTS1-binding domain. A crystal structure of the 
TPRs is shown above (PDB ID: 1FCH), the colors range from red to green, corresponding to TPRs 1 to 7. 
 
3.2.4. Docking and insertion of the receptor-cargo complex into the DTM and cargo 
release 
After cargo recognition in the cytosol, PEX5 interacts with the docking/translocation 
module (150–152). As previously mentioned, the DTM comprises PEX14, PEX13 and the 
RING finger proteins PEX2, PEX10 and PEX12, all peroxisomal transmembrane proteins 
(79, 81). The overall architecture of this protein complex remains unknown. From all these 
components, at least PEX14 and PEX13 have the ability to form homo-oligomers (81, 144, 
153–155) and to interact with the N-terminal domain of PEX5 (see section I-3.2.3.). Thus, 
these two proteins are most likely the main components of the peroxisomal protein 
translocon (reviewed in (156, 157)). 
The interaction between the receptor-cargo complex and the DTM happens in two 
distinct steps: docking followed by insertion. Docking of the PEX5-cargo protein complex at 
the organelle surface is a reversible step that can occur even at low temperatures (0 ºC) 
(152). On the contrary, its insertion is only observed at higher temperatures (> 16 ºC) and is 
an irreversible event in the absence of ATP (152, 158). Importantly, this insertion step is 
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cargo-dependent, meaning that it only occurs when PEX5 is in complex with a cargo protein 
(150). Strikingly, truncated versions of PEX5 lacking the TPRs, as well as a PEX5 protein 
with the N526K mutation that abrogates its PTS1-binding activity, are capable of inserting 
into the DTM (102, 150, 159). These and other observations led to the proposal that the 
insertion of PEX5 into the peroxisomal membrane is a process regulated by PEX5 itself (150, 
159). According to this model, the C-terminal half of PEX5 is a cis-acting repressor of the N-
terminal DTM-interacting domain of PEX5. Repression is abolished when PEX5 binds a 
cargo protein (see (160)). 
When PEX5 becomes inserted into the DTM, it acquires a transmembrane topology, 
exposing most of its polypeptide chain into the organelle matrix, and only a small 2-kDa 
fragment of its N-terminus into the cytosol. This finding suggests that cargo proteins are 
translocated across the peroxisomal membrane by their own receptor (151, 161). The 
insertion/cargo-translocation step is ATP-independent, since ATP-depleted conditions (such 
as the presence of non-hydrolysable ATP analogs or treatment with ATP-
diphosphohydrolases) do not compromise insertion of PEX5 into the peroxisomal membrane 
(162) nor the translocation of PTS1- and PTS2-containing proteins into the organelle matrix 
(152, 163). This observation, together with data showing that ionophores have no effect on 
protein import into peroxisomes (163–165), suggest that the protein-protein interactions 
established between PEX5 and the components of the DTM are the driving force for cargo 
protein translocation across the peroxisomal membrane (162, 166). 
Interestingly, cargo release from DTM-bound receptor into the organelle matrix is also 
ATP-independent. Possibly, PEX5(.PEX7) suffer(s) DTM-induced conformational alterations 
that decrease their cargo-binding affinity and thus enable the release of cargo into organelle 
matrix (107, 116, 167). 
Once the cargo protein is in its final destination, the receptor PEX5 has to be 
extracted from the peroxisomal membrane in order to participate in a new protein transport 
cycle. The extraction of PEX5 comprises two distinct events: 1) monoubiquitination of PEX5, 
and 2) its dislocation back into the cytosol. 
 
3.2.5. Monoubiquitination of PEX5 
PEX5 is monoubiquitinated during its transient passage through the peroxisomal 
membrane (147, 148). As previously mentioned, DTM-embedded PEX5 exposes into the 
cytosol a 2-kDa N-terminal domain (151). This small domain includes the highly conserved 
cysteine residue (Cys11 in human PEX5) that is the acceptor of ubiquitin (147, 148). 
Monoubiquitination of PEX5 depends on the ubiquitin-conjugating cascade, which comprises: 
an ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2) and an ubiquitin 
ligase (E3) (168). In mammals, the E2 activity is provided by cytosolic E2D1/2/3 (UbcH5a/b/c 
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in humans) (85). These are three multipurpose E2s involved in many other biological 
pathways (169, 170). Yeast, other fungi and plants, contrary to mammals, have a 
peroxisomal E2. This is PEX4, which is anchored by PEX22 to the peroxisomal membrane 
(148, 171–174). The E3 activity is attributed to the DTM RING finger peroxins PEX2, PEX10 
and PEX12 (175–178), which contain RING Zn2+-binding domains that define the largest 
class of E3 ligases (179). However, the exact role of each one of these peroxins in this event 
remains unknown. 
Generally, ubiquitin is attached to a lysine residue of a substrate protein via an 
isopeptidic bond involving the carboxyl-terminus of ubiquitin and the ε-amine group of that 
lysine (168). As stated above, monoubiquitination of PEX5 occurs at a cysteine residue, via a 
thioester bond (147). The reason why PEX5 is ubiquitinated at a cysteine is still not well 
understood. An engineered PEX5 having a lysine at position 11 (instead of the cysteine) is 
able to insert into the DTM, acquire an ubiquitin and be dislocated to the cytosol as efficiently 
as wild-type PEX5 (180). Therefore, some hypotheses have been formulated suggesting an 
additional function/regulatory role for the conserved cysteine. Experimental evidence has 
been provided showing that Cys11 in human PEX5 functions as a redox switch, regulating 
PEX5 activity (and, thus, the cytosolic/peroxisomal localization of peroxisomal proteins) in 
response to intracellular oxidative stress (181, 182). It is possible that compromising the 
import of newly synthesized peroxisomal matrix proteins (such as catalase), is advantageous 
to the cell under oxidative stress conditions in the cytosol (10, 180, 181). Another possible 
explanation for the ubiquitination at a cysteine residue is that it might prevent the degradation 
of cytosolic ubiquitinated PEX5 by the ubiquitin-proteasome pathway (180, 183). Indeed, the 
extreme lability of the thioester bond linking ubiquitin to PEX5 under physiological conditions 
may decrease the probability of monoubiquitinated PEX5 being polyubiquitinated and 
targeted to the proteasome. 
Monoubiquitination of PEX5 is absolutely mandatory for the next step of the pathway 
– the dislocation of PEX5 back into the cytosol (147, 184). Indeed, N-terminal truncated 
version of PEX5 without the first 17 amino acid residues (lacking the conserved Cys11) 
(158), as well as PEX5 with the Cys11 replaced by an alanine (a non-ubiquitinatable 
residue), are both unable to return to the cytosol (159). 
 
3.2.6. PEX5 dislocation to the cytosol 
Dislocation of monoubiquitinated PEX5 (Ub-PEX5) is an ATP-hydrolysis dependent 
event (162) and is mediated by the receptor export module, which comprises the two AAA 
ATPases PEX1 and PEX6, and their membrane anchor PEX26 (82–84). Some data 
suggesting that AWP1, an ubiquitin-binding protein, is also a component of the REM are also 
available (185). This step is very fast in the presence of ATP (158, 186). However, the 
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mechanistic details of how Ub-PEX5 is recognized by the REM and how its 
mechanoenzymes dislocate Ub-PEX5 back into the cytosol are not yet understood. It is 
possible that the ubiquitin in the DTM-embedded Ub-PEX5 activates the REM by providing a 
context-specific protein interface. In fact, monoubiquitination of PEX5 with a GST-Ub fusion 
protein, a bulky ubiquitin analog, blocks completely the export of PEX5 (147). This might 
suggest that the Ub-PEX5 recognition by the REM includes a direct interaction between 
ubiquitin and the REM. Nevertheless, other interactions with the REM may occur. Indeed, it 
was recently proposed that PEX14 and PEX5 can also interact directly with REM (187). 
Recently, the structure of yeast PEX1/PEX6 complex has been determined (188–
190). The two AAA ATPases form a heterohexamer composed by a trimer of PEX1/PEX6 
dimers (188–191). However, the available data are not enough to reveal how this complex 
works (reviewed in (191)). Nevertheless, by analogy with other AAA ATPases it was 
suggested that the substrate of the REM is moved through the central pore of the 
PEX1/PEX6 complex (191). In agreement with that hypothesis, a recent study showed that 
PEX5 fused to a tightly folded, bulky, C-terminal tag (EGFP), is monoubiquitinated in the 
DTM and is a substrate for the REM. However, PEX5-EGFP is only partially extracted from 
the peroxisomal membrane. Indeed, it was shown that the Ub-PEX5 portion of Ub-PEX5-
EGFP is exposed into the cytosol whereas the EGFP moiety and some PEX5 C-terminal 
residues remained associated with the organelle, probably blocked at the REM. Thus, the 
presence of the tightly folded tag at the C-terminus of PEX5 compromises its export, 
presumably because the REM cannot thread tightly folded domains (192). 
Extraction of PEX5 from the DTM is the only process of the peroxisomal matrix 
protein import pathway that needs ATP hydrolysis (162). Thus, unlike other protein import 
machineries that use the energy input from ATP/GTP hydrolysis for the vectorial transport 
proteins through a membrane (193, 194), the PIM consumes energy not for the protein 
translocation process, but rather to reset the protein transport pathway. 
 
3.2.7. Deubiquitination of PEX5 
Once in the cytosol, Ub-PEX5 is deubiquitinated, most likely by a combination of 
enzymatic and non-enzymatic mechanisms (180). The first, is probably carried out by 
ubiquitin-specific protease 9X (USP9X), the most active mammalian deubiquitinase acting on 
soluble Ub-PEX5 (86). The second may involve nucleophiles, such as glutathione. Indeed, it 
was shown that the thioester bond linking ubiquitin to PEX5 is easily disrupted by 
physiological concentrations of glutathione (180). Since Ub-PEX5 was never detected in 
cytosolic fractions obtained from rat liver or yeast cells, its deubiquitination is possibly very 
fast in vivo (148, 180). 
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Deubiquitination of PEX5 is the last step of the import of peroxisomal matrix proteins. 
Now, free soluble PEX5 can participate in a new protein transport cycle. 
 
 
4. Peroxisome homeostasis 
As previously mentioned, peroxisomes are crucial for numerous metabolic pathways, 
including the metabolism of hydrogen peroxide and the β-oxidation of fatty acids (11, 12). As 
a result, cells have to ensure the homeostasis of peroxisomes, by controlling their 
abundance and quality, in order to maintain a healthy intracellular environment. This 
requires, on one side, the biogenesis of new organelles, and, on the other, the degradation of 
excessive or dysfunctional ones (195, 196). As stated above, it is commonly accepted that 
peroxisomes multiply by growth and division of mature peroxisomes. The turnover of 
unnecessary or dysfunctional peroxisomes mainly occurs by pexophagy, i.e., the specific 
autophagic degradation of the peroxisome. 
 
4.1. Proliferation of peroxisomes by “growth and division” of mature peroxisomes 
Peroxisome proliferation encompasses membrane elongation (growth), constriction 
and scission (division). This is a multi-step process mediated by PEX11 peroxin, as well as 
the mitochondrial fission factor (Mff), fission factor 1 (Fis1), dynamin-like protein 1 (DLP1), 
and ganglioside induced differentiation associated protein 1 (GDAP1) (reviewed in (197)). In 
mammals, three isoforms of PEX11 exist, PEX11α, PEX11β and PEX11γ. All of them are 
integral membrane proteins exposing both the N- and C-termini into the cytosol (198–201). 
While PEX11β is constitutively expressed, PEX11α and PEX11γ are expressed in a tissue-
specific manner (198, 200). Mff, Fis1, DLP1 and GDAP1 proteins are shared with 
mitochondria. During peroxisome proliferation, PEX11β is responsible for the peroxisomal 
membrane remodeling and elongation, and perhaps for the following assembling of Mff and 
Fis1 proteins. These proteins can recruit cytosolic DLP1, which is required for membrane 
scission. The exact function of Mff, Fis1 and GDAP1 proteins is unclear (reviewed in (197)). 
In yeasts, besides PEX11, other additional and related peroxins have been associated with 
peroxisome proliferation (202). 
 
4.2. Degradation of peroxisomes by pexophagy 
Autophagy is the intracellular process by which cytoplasmic components, including 
proteins and organelles, are delivered to the lysosome in order to be degraded. There are 
three types of autophagy – macroautophagy, microautophagy, and chaperone-mediated 
autophagy (reviewed in (203)) – but for the present discussion only the first type is relevant.  
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During macroautophagy, an isolation membrane, also named phagophore, encloses 
cytoplasmic components to form an intermediate organelle called autophagosome. This 
autophagosome fuses with the lysosome to become an autolysosome, where the internal 
components are degraded. Macroautophagy can occur both non-selectively or selectively. 
The selective pathway involves specific receptors that recognize specific substrates targeted 
for degradation and interact with other components of the macroautophagy machinery (203). 
Pexophagy is a selective form of macroautophagy. 
p62 and NBR1 were identified as pexophagy receptors in mammalian cells (204, 
205). They both contain 1) an ubiquitin-associated (UBA) domain, that recognizes 
ubiquitinated substrates, and 2) an LC3-interacting region, that interacts with the LC3 protein 
present at the autophagosomal membranes (206). Overexpression of peroxisomal 
membrane proteins (PMP34 and PEX3) attached to an ubiquitin moiety facing the cytosol, 
resulted in loss of peroxisomes within cells in a p62-dependent manner (204). On the other 
hand, overexpression of NBR1 also triggers pexophagy, being the NBR1 UBA and J (a 
membrane-interacting, amphipathic α-helix region) domains necessary for degradation of 
peroxisomes (205). Overexpression of PEX3 also induces pexophagy in an ubiquitin-
dependent mode (207). Thus, these studies suggest that the presentation of ubiquitin at the 
surface of the organelle is important for peroxisome recognition during pexophagy in 
mammalian cells. 
Evidence for a quality control mechanism to eliminate dysfunctional peroxisomes in 
mammalian cells was recently provided (192). The expression of a PEX5 protein that is 
monoubiquitinated at Cys11 but export-incompetent due to a bulky C-terminal tag, results in 
the accumulation of ubiquitinated PEX5 at the peroxisomal membrane, and triggers 
pexophagy in SV40 large T antigen-transformed mouse embryonic fibroblasts. This study 
showed that alterations in PEX5 and ubiquitin dynamics at the peroxisome membrane can 
regulate the mammalian pexophagy (192). Accordingly, the depletion of REM function 
causes the loss of peroxisomes by pexophagy in yeast and mammalian cells (208, 209). 
However, while in S. cerevisiae, the accumulation of import receptors at the peroxisomal 
membrane is not required for pexophagy (208), in mammalian cells, the accumulation of 
ubiquitinated PEX5 signaled peroxisomes for pexophagy (209). The latter study suggests 
that the REM prevents mammalian pexophagy by extracting ubiquitinated proteins from 
peroxisomes (209). 
 
 
5. Unsolved questions regarding the import of matrix proteins into peroxisomes 
Although, in the last years, our knowledge on the peroxisomal matrix protein import 
machinery has increased extraordinarily, many of its “details” are still unknown. For instance, 
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we still have no idea of why there are three RING peroxins in the DTM, or how the REM 
recognizes and extracts ubiquitinated receptors. However, perhaps the most intriguing 
property of the PIM regards its ability to import already folded and even oligomerized proteins 
(reviewed in (126, 127, 210)). This leads us to one of the most important questions about the 
PIM: how can the PIM accept already folded proteins as substrates while at the same time 
ensuring that matrix proteins are retained in the organelle. Two main models have been 
proposed (see below), but, the data supporting each these perspectives are indirect and still 
scarce. 
Our group proposed the model presented in the previous sections, where newly 
synthesized folded matrix proteins are translocated across the peroxisomal membrane by 
PEX5 itself, when the receptor becomes inserted into the DTM (151, 161, 166, 211). This 
model proposes that the soluble receptor-cargo complex is recruited into a proteinaceous 
pore/channel formed by the DTM components, and takes into account: 1) the 
transmembrane topology of DTM-embedded PEX5 (151, 211), 2) the absence of any 
obvious phylogenetically conserved hydrophobic or amphipathic domain in PEX5 (PEX5 is a 
particularly hydrophilic protein), and 3) the fact that the region that contains the DTM-
interacting domains of PEX5, its natively unfolded N-terminal half, remains in solution even 
upon boiling (140). 
The second model, the so-called “transient pore model” (212), proposes that PEX5 is 
a pore-forming toxin-like protein. In essence that model is similar to the one described above, 
i.e., it also proposes that cargo proteins are pushed across the organelle membrane by 
PEX5 itself, when the receptor interacts with the DTM. However, it introduces the novelty that 
the pore is formed by a combination of PEX5 molecules and DTM components, all of them 
interacting directly with the lipid bilayer of the peroxisomal membrane, and all together 
creating the hydrophilic pore that allows the translocation of cargo proteins across the 
membrane (212, 213). The data that supports this model, excluding at the same time the 
model from our group, can be reduced to a single experimental fact: peroxisome-associated 
PEX5 is resistant to alkaline extraction, a property generally attributed to intrinsic membrane 
proteins. 
Clearly, all these issues have to be clarified if we are to understand how this 
remarkable protein sorting machinery works. 
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The study here presented focused on two aspects of the peroxisomal matrix protein 
import machinery. 
The first aim of this study was to explore the role of PEX5 as a holdase-like protein. 
Recently, our laboratory proposed that PEX5, in addition to its role as a shuttling receptor 
that recognizes newly synthesized peroxisomal matrix proteins in the cytosol and targets 
them to the organelle, is also a holdase-like protein that avoids premature or unspecific 
interactions of its cargo proteins in the cytosol (107, 132). In this study, several approaches 
commonly used to assess the holdase activity of a given protein were applied to PEX5. 
The second aim of this study was to probe the architecture of the peroxisomal matrix 
protein translocon. Initially, the intriguing biochemical behavior of peroxisomal PEX5, i.e., its 
resistance to alkaline extraction (211), that has been interpreted in different ways resulting in 
quite different models concerning the mechanism of the PIM (161, 212), was revisited. Then, 
an established cell-free organelle-based in vitro system (87) and several truncated versions 
of PEX5 were used to probe the DTM architecture. 
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III - EXPERIMENTAL PROCEDURES 
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1. DNA constructs 
 
pET-28-PEX5 – The cDNA encoding the large isoform of human PEX5 ((78); hereafter 
referred to as PEX5) was obtained by PCR amplification of the plasmid pQE-30-PEX5 (138) 
using the primers 5’.GCGAACTGCATATGGCAATGCGGGAGCTGG.3’ and 
5’.GCGTAATTAAGCTTGGCTGCAGGTC.3’. The amplified DNA fragment was digested with 
NdeI and SalI and cloned into the NdeI/SalI restriction sites of pET-28c (Novagen). 
 
pET-28-PEX5(C11A) – To obtain the plasmid encoding PEX5 possessing an alanine instead 
of a cysteine at position 11 (PEX5(C11A)), plasmids pET-28-PEX5 and pET-28-PEX5(1-
324;C11A) (186) were digested with NcoI and SdaI. The 0.3 kb NcoI/SdaI fragment of pET-
28-PEX5(1-324;C11A) was inserted into the NcoI/SdaI-digested vector pET-28-PEX5. 
 
pET-28-PEX5(1-197;C11A) – The cDNA encoding the first 197 amino acid residues of PEX5 
possessing an alanine at position 11 (PEX5(1-197;C11A)) was obtained by PCR 
amplification of the plasmid pET-28-PEX5(1-324;C11A) using the primers 
5’.CTCGATCCCGCGAAATTAATACGACTC.3´ and 
5’.CGCCAAGCTTTTACGTGTGCTGCAGATCCTCCTC.3’. The amplified DNA fragment was 
digested with XbaI and HindIII and cloned into the XbaI/HindIII restriction sites of pET-28a 
(Novagen). 
 
pET-28-PEX5(1-125;C11A) – The cDNA encoding the first 125 amino acid residues of PEX5 
possessing an alanine at position 11 (PEX5(1-125;C11A)) was obtained by PCR 
amplification of the plasmid pET-28-PEX5(1-324;C11A) using the primers 
5’.GATGCGTCATATGGCAATGCGGGAGCTGGT.3’ and 
5’.GATCGCAAGCTTTCAAGCTGCAAGAAACTCCTG.3’. The amplified DNA fragment was 
digested with NdeI and HindIII and cloned into the NdeI/HindIII restriction sites of pET-28a 
(Novagen). 
 
pET-28-PEX5(1-324;C11K) – The plasmid encoding the first 324 amino acid residues of 
PEX5 possessing a lysine instead of a cysteine at position 11 (PEX5(1-324;C11K)) was 
obtained with the QuikChange® site-directed mutagenesis kit (Agilent Technologies), using 
pET-28-PEX5(1-324) (85) as template and the primers described elsewhere (180). 
 
pET-28-PEX5(1-197;C11K) – To obtain the plasmid encoding the first 197 amino acid 
residues of PEX5 possessing a lysine at position 11 (PEX5(1-197;C11K)), plasmids pET-28-
PEX5(1-324;C11K) and pET-28-PEX5(1-197;C11A) were digested with EcoRV and SdaI. 
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The 1.5 kb EcoRV-SdaI fragment of pET-28-PEX5(1-324;C11K) was inserted into the 
EcoRV-SdaI-digested vector pET-28-PEX5(1-197;C11A). 
 
pET-28-PEX5(1-125;C11K) – To obtain the plasmid encoding the first 125 amino acid 
residues of PEX5 possessing a lysine at position 11 (PEX5(1-125;C11K)), plasmids pET-28-
PEX5(1-324;C11K) and pET-28-PEX5(1-125;C11A) were digested with EcoRV and SdaI. 
The 1.5 kb EcoRV-SdaI fragment of pET-28-PEX5(1-324;C11K) was inserted into the 
EcoRV-SdaI-digested vector pET-28-PEX5(1-125;C11A). 
 
pET-28-PEX5(1-125;C11K)-clv – This plasmid encodes PEX5(1-125;C11K) protein fused to 
amino acid residues 1 to 30 of human pre-thiolase harboring the L4R mutation, which 
abolishes its PTS2 function (214), followed by the first 19 residues of the human sterol carrier 
protein-2 (SCP2) precursor (PEX5(1-125;C11K)-clv). The synthetic gene encoding PEX5(1-
125;C11K) possessing at its C-terminus the polypeptide 
MQRRQVVLGHLRGPADSGWMPQAAPC*LSGAGFPEAASSFRTHQVSAAPT was codon 
optimized for expression in rabbit reticulocyte lysate, synthesized and cloned into the 
NdeI/BamHI sites of pET-28a (Novagen) by Genscript. The cleavage site for the peroxisomal 
matrix protease Tysnd1 is marked with an asterisk (94, 97) and the 19 residues of the SCP2 
precursor are in italic. 
 
pET-28-PEX5(1-125;C11K)-nclv – This plasmid is nearly identical to pET-28-PEX5(1-
125;C11K)-clv but encoding a fusion protein lacking the -2 and -1 residues of the Tysnd1 
cleavage site (Pro25 and Cys26, numbering of full-length human pre-thiolase, underlined in 
sequence above); constructed in the exact same way by Genscript. 
 
cDNA PEX5(1-197;C11A) – The cDNA encoding amino acid residues 1 to 197 of PEX5 
possessing an alanine at position 11 (PEX5(1-197;C11A)), without the N-terminal histidine 
tag and preceded by a T7 RNA polymerase promoter, was obtained by PCR amplification of 
the plasmid pGEM4-PEX5(C11A) (180) using the primers 
5’.GCCCAATACGCAAACCGCCTCTCC.3’ and 
5’.GATAATCACGTGTGCTGCAGATCCTCCTCAGG.3’. 
 
2. Expression and purification of recombinant proteins 
Recombinant histidine-tagged PEX5, PEX5(C11A), PEX5 containing the missense 
mutation N526K (PEX5(N526K); (159)), a protein comprising amino acid residues 138 to 639 
of PEX5 (PEX5(ΔN137); (215)) (138), a protein comprising amino acid residues 315 to 639 
of PEX5 (TPRs) (102, 140), a protein comprising amino acid residues 1 to 324 of PEX5 
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(PEX5(1-324)), a protein comprising amino acid residues 1 to 197 of PEX5 (PEX5(1-
197;C11A)) (87), a protein comprising the first 80 amino acid residues of human PEX14 
(NDPEX14) (140), and human PEX19 (68), were produced as described before. The N-
terminal histidine tag of PEX5(ΔN137) was removed using histidine-tagged TEV (Tobacco 
Etch Virus) protease in 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA-NaOH, pH 8.0, 
1 mM DTT, overnight at 4 ºC. The protein solution was then incubated with HIS-Select Nickel 
Affinity Gel beads (Sigma) for 2 hours at 4 ºC, and PEX5(ΔN137) was recovered in the non-
bound fraction. The protein was concentrated by repeated centrifugation and dilution using 
Vivaspin® 2 sample concentrators, as described before (87). 
 
3. Thermal-induced aggregation of malate dehydrogenase 
The holdase-like activity of PEX5 was studied using commercially available malate 
dehydrogenase (MDH) from porcine heart (Sigma, cat. no. M1567) as substrate protein, as 
described in (216). MDH (2 µM final concentration) was incubated in 250 µL of 50 mM Tris-
HCl, pH 8.0 buffer, in the absence or presence of PEX5(1-324) (10 µM final concentration) or 
BSA (10 µM final concentration), at 43 ºC for 90 min. The aggregation of MDH was followed 
by measuring light scattering at 340 nm in a temperature controlled spectrophotometer 
(Shimadzu UV-2401PC). Three independent experiments for each condition were performed. 
 
4. Thermal-induced inactivation of citrate synthase 
The holdase-like activity of PEX5 was studied using commercially available citrate 
synthase (CS) from porcine heart (Sigma, cat. no. C3260) as substrate protein, as described 
in (217). Samples of CS (final concentration of 0.15 µM for monomer) in the absence or 
presence of PEX5(1-324) (final concentration of 250 µM) or BSA (final concentration of 250 
µM) were prepared in a 50-µL final volume of 50 mM Tris-HCl, pH 8.0, 2 mM EDTA-NaOH, 
and kept on ice. A 5 µL-aliquot was taken to measure the activity of CS at zero time, which 
was set to 100%. The inactivation of CS was then started by sample incubation at 44 ºC, with 
stirring. 5 µL-aliquots were taken at indicated time points (2, 5, 10, 20 and 30 min) to 
determine the remaining activity of CS. For each enzyme activity assay, the 5 µL-aliquot was 
mixed with 245 µL of 50 mM Tris-HCl, pH 8.0, 2 mM EDTA-NaOH, 10 µM oxaloacetic acid, 
15 µM acetyl-CoA, 10 µM Ellman’s Reagent, previously incubated at 25 ºC, and the 
absorbance at 412 nm was recorded for 4 min at room temperature. The values obtained 
were used to determine the percentage of CS activity. Four independent experiments for 
each condition were performed. 
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5. In vitro synthesis and folding of luciferase 
This assay was adapted from (218). Luciferase was synthesized in vitro using the 
TnT® T7 Quick Coupled Transcription/ Translation System (Promega), the plasmid DNA 
provided by the kit, and EasyTag L-35S-methionine (specific activity >1000 Ci (37.0 
TBq)/mmol; PerkinElmer Life Sciences). Different transcription/translation reactions were 
prepared in the presence of 0.1 mM luciferin and in the presence of either 0.5 µM 
recombinant PEX5, 0.5 µM PEX5(N526K), 0.5 µM PEX5 plus 50 µM of a PTS1-containing 
peptide (CRYHLKPLQSKL), or 0.5 µM PEX5 plus 50 µM of a negative control peptide 
(CRYHLKPLQLKS). The transcription/translation reactions were incubated into a 
luminometer at 25 ºC, and the light emission during synthesis was recorded during 1 hour. 
 
6. Size-exclusion chromatography at pH 11.5 
Recombinant proteins PEX5 (180 µg), PEX5(1-324) (125 µg), and NDPEX14 (300 
µg), as well as mixtures containing either PEX5 and NDPEX14 or PEX5(1-324) and 
NDPEX14, were incubated in 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA-NaOH, 
pH 8.0, 1 mM DTT (final volume of 50 µL) for 15 min at 23 ºC. Samples were then diluted 
with 200 µL of 0.15 M sodium carbonate (pH after dilution = 10.9), incubated for 30 min on 
ice, and a 200 µL-aliquot was injected into a SuperoseTM 12 10/300 GL column running with 
0.12 M Na2CO3, 0.5 mM DTT (pH 11.6), at 4 ºC, and at a flow rate of 0.5 mL/min. Fractions 
of 0.5 mL were collected and 30-µL aliquots were analyzed by SDS-PAGE/Coomassie blue 
staining. 
 
7. Preparation of rat liver post-nuclear supernatant 
Liver post-nuclear supernatant (PNS) was prepared from overnight-fasted Wistar Han 
male rats with 6 to 10 weeks of age, exactly as described in (87). Briefly, the liver was 
collected, washed and quickly homogenized in ice-cold SEM buffer (0.25 M sucrose, 20 mM 
MOPS-KOH, pH 7.2, 1 mM EDTA-NaOH, pH 8.0) supplemented with 2 µg/mL of N-(trans-
epoxysuccinyl)-l-leucine 4-guanidinobutylamide (E-64). The homogenate was centrifuged 
twice at 600 g for 10 min at 4 oC (SS-34 rotor in a RC5B Sorvall® centrifuge). Single-use 
aliquots of the final supernatant were frozen in liquid nitrogen and stored at -80 oC. Protein 
concentration of the PNS was determined by the Bradford method. 
 
8. In vitro synthesis of radiolabeled proteins in rabbit reticulocyte lysate 
35S-methionine-labeled proteins were synthesized in vitro using the TnT® T7 Quick 
Coupled Transcription/Translation System (Promega), according to manufacturer’s 
instructions. Briefly, the TnT® Quick Master Mix was mixed with EasyTag L-35S-methionine 
(specific activity >1000 Ci (37.0 TBq)/mmol; PerkinElmer Life Sciences) and the plasmid 
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DNA or cDNA template, and the reaction was incubated for 90 min at 30 oC. An aliquot of the 
rabbit reticulocyte lysate (RRL) containing the radiolabeled protein was analyzed by SDS-
PAGE/autoradiography to verify yields and quality of the radiolabeled protein. 
Unless otherwise specified, 35S-labeled proteins were synthesized in vitro as N-
terminally histidine-tagged fusion proteins from pET-28-derived plasmids. Syntheses yields 
from these plasmids were significantly larger than those obtained with pGEM-4-derived 
plasmids, used in previous works (e.g., (180)). For radiolabeled PEX5(C11A), a semi-
quantitative western-blot analysis using the recombinant protein as a standard and a Tetra-
his antibody (see section III-17) revealed yields of about 20 ng/µL of RRL. Yields were 2-3 
fold larger for PEX5(1-197;C11A/K) and PEX5(1-324;C11A/K), as assessed by quantitative 
autoradiography using radiolabeled PEX5(C11A) as a standard, and taking into account the 
methionine content of each protein. 
 
9. Cell-free PNS-based in vitro assays 
PNS-based in vitro reactions were performed as recently described (87), with 600 μg 
of total PNS protein and 0.1 to 16 μL of RRL containing the indicated 35S-labeled protein, per 
100 μL of reaction, in import buffer (0.25 M sucrose, 20 mM MOPS-KOH, pH 7.2, 50 mM 
KCl, 3 mM MgCl2, 2 μg/mL E-64, 96 μg/mL methionine) supplemented with 2 mM reduced L-
glutathione, pH ~7.0 with NaOH, 10 μM bovine ubiquitin, and 5 mM ATP or 5 mM AMP-PNP. 
In the latter case, the PNS was previously primed for import by incubating it for 5 min at 37 
oC in the presence of 0.3 mM ATP. The priming of PNS allows endogenous DTM-embedded 
PEX5 to be exported back into the soluble fraction, thus increasing the number of free DTMs 
available. Where indicated, ubiquitin aldehyde, a potent and highly specific inhibitor of 
deubiquitinases (219), was used at 1 μM final concentration. Where indicated, the reactions 
were additionally supplemented with recombinant NDPEX14, PEX5(1-197;C11A), 
PEX5(C11A), TPRs, PEX5(1-324), PEX19 or PEX5(ΔN137) (as specified in the respective 
figure legends). PNS-based in vitro reactions were incubated for 45 min at 37 oC (unless 
otherwise specified), and treated with 400 μg/mL (final concentration) of proteinase K (PK) 
for 40 min on ice, to degrade protein that had not associated with peroxisomes, followed by 
PK inactivation with 500 μg/mL (final concentration) of phenylmethanesulfonyl fluoride. In 
vitro reactions were then diluted to 1 mL with SEMK buffer (SEM buffer supplemented with 
80 mM KCl) and the organelles were isolated by centrifugation at 11300 g for 15 min at 4 oC. 
Proteins were precipitated with 10% (w/v) trichloroacetic acid (TCA) for 30 min on ice, and 
recovered by centrifugation at 11300 g for 15 min at 4 oC. Protein pellets were washed with 1 
mL acetone, centrifuged again at 11300 g for 15 min at 4 oC, dried at 37 oC, and analyzed by 
SDS-PAGE/autoradiography. In the two-step in vitro import/export assays, 35S-labeled 
proteins were first incubated with the primed PNS for 30 min at 37 oC in the presence of 
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AMP-PNP. The reactions were then diluted to 1 mL with SEMK buffer and the organelles 
isolated by centrifugation at 11300 g for 15 min at 4 oC. The organelles were resuspended in 
import buffer and incubated in the presence of either 5 mM ATP or 5 mM AMP-PNP for 15 
min at 37 oC. The organelle suspensions were then diluted to 1 mL with SEMK buffer and 
centrifuged at 11300 g for 15 min at 4 oC. Proteins of both organelle and soluble fractions 
were precipitated with 10% (w/v) TCA, processed as described above, and analyzed by 
SDS-PAGE/autoradiography. 
 
10. Digestion with Genenase I 
Organelles from a PK-treated PNS-based in vitro reaction programmed with 35S-
PEX5(1-197;C11A), or 0.25 µL of RRL containing 35S-PEX5(1-197;C11A), were digested 
with 2 μg of Genenase I (New England BioLabs; (220)) in a buffer containing 0.25 M sucrose, 
20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1% (w/v) Triton X-100, 1 mM EDTA-NaOH, pH 8.0, 1 
mM DTT, 50 µg/mL phenylmethanesulfonyl fluoride, and 1:300 (v/v) mammalian protease 
inhibitor mixture (Sigma), for 30 min at 23 ºC. Digestions were stopped with 10% (w/v) TCA, 
processed as described above, and analyzed by SDS-PAGE/autoradiography. 
Recombinant PEX5(1-197;C11A) (1 μg) was incubated in 50 mM Tris-HCl, pH 8.0, 
150 mM NaCl, 1 mM EDTA-NaOH, pH 8.0, 1 mM DTT (final volume of 10 µL) for 3 h 30 m at 
23 ºC, in the absence or presence of 0.25 μg of Genenase I. Samples were analyzed by 
SDS-PAGE/Coomassie blue staining and by mass spectrometry. 
 
11. Mass spectrometry analyses 
Mass spectra were acquired in a MALDI mass spectrometer (4800 Plus MALDI 
TOF/TOD Analyzer, SCIEX) using the 4000 Series Explorer v3.7.0 (build 1) SCIEX software, 
at i3S Proteomics Core Facility (Portugal) by Doctor Hugo Osório. For peptide molecular 
mass determination, samples were diluted 10-fold in 10 mg/mL of α-Cyano-4-
hydroxycinnamic acid (50% ACN, 0.1% TFA) and 1 μL was spotted in a MALDI sample plate 
and allowed to dry. Spectra were acquired in reflector positive mode for the mass range m/z 
1000 - m/z 3000 with and without internal standards (Angiotensin I, DRVYIHPFHL, m/z 
1296.68, ACTH 1-17, SYSMEHFRWGKPVGKKR, m/z 2093.09, and ACTH 18–39, 
RPVKVYPNGAEDESAEAFPLEF, m/z 2465.20). For protein molecular mass determination, 
samples were diluted 10-fold in 10 mg/mL of sinapic acid matrix (50% ACN, 0.1% TFA), and 
1 μL was spotted in the MALDI sample plate and allowed to dry. Mass spectra were acquired 
in linear positive mode for the mass window m/z 15000 - m/z 35000.  Mass spectra were 
internally calibrated with horse apomyoglobin, m/z 16952. For determination of protein 
cleavage location, data analysis was performed with the Findpept software ((221); 
 35 
 
http://web.expasy.org/findpept/). The maximum allowed error was 10 ppm for peptide 
masses. 
 
12. Density gradient centrifugation 
A PK-treated PNS-based in vitro reaction (4.8 mg of total PNS protein) was diluted to 
1.6 mL with SEM buffer, and loaded onto the top of a Histodenz™ step gradient comprising 
1.5 mL of 45% (w/v), 5.5 mL of 28% (w/v), and 1 mL of 20% (w/v) Histodenz™ in 5 mM 
MOPS-KOH, pH 7.2, 1 mM EDTA-NaOH, pH 8.0. The gradient was centrifuged at 82500 g 
for 3 h at 4 ºC (70.1 Ti rotor in an Optima™ L-80 XP Beckman Coulter ultracentrifuge), and 
12 fractions were collected from the bottom of the gradient. After protein precipitation with 
10% (w/v) TCA, ¼ of each fraction was analyzed by SDS-PAGE/western-blotting/ 
autoradiography. After exposing to an x-ray film, the nitrocellulose membrane was probed 
with several antibodies, as indicated. 
 
13. Extraction of peroxisomal proteins by sonication 
Organelles from a PK-treated PNS-based in vitro reaction were resuspended in SEM 
buffer supplemented with 2 mM DTT, 0.1 mg/mL phenylmethanesulfonyl fluoride, and 1:500 
(v/v) mammalian protease inhibitor mixture (Sigma), and disrupted by sonication as 
described before (186). Membrane and matrix components were separated by centrifugation 
at 100000 g for 60 min at 4 ºC (70.1 Ti rotor in an Optima™ L-80 XP Beckman Coulter 
ultracentrifuge). After protein precipitation with 10% (w/v) TCA, samples were analyzed by 
SDS-PAGE/western-blotting/autoradiography. After exposing to an x-ray film, the 
nitrocellulose membrane was probed with several antibodies, as indicated. 
 
14. SDS-PAGE/autoradiography 
Protein samples were solubilized in Laemmli sample buffer (50 mM Tris-HCl, pH 8.8, 
2% (w/v) SDS, 0.017% (w/v) bromophenol blue, 10% (v/v) glycerol, 2 mM EDTA-NaOH, pH 
8.0, 100 mM DTT) by incubation for 10 min at 65 ºC followed by 5 min at 95 ºC, and loaded 
onto SDS polyacrylamide gels (16.5 cm x 14.5 cm x 0.75 mm). Typically, gels were blotted 
onto a nitrocellulose membrane for autoradiography. For quantitative autoradiography, the 
gels were instead stained with 0.2% (w/v) Coomassie, 50% (v/v) methanol, and 10% (v/v) 
glacial acetic acid, dried for 2 hours at 80 oC, and exposed to a storage phosphor screen. 
 
15. PAGE at pH 11.5 
Recombinant proteins PEX5 (2 µg), PEX5(1-324) (2 µg), and NDPEX14 (5 µg), as 
well as mixtures containing either PEX5 and NDPEX14 or PEX5(1-324) and NDPEX14, were 
incubated in 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA-NaOH, pH 8.0, 1 mM DTT 
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(final volume of 2 µL) for 15 min at 23 ºC. Samples were diluted with 8 µL of 25 mM 
phosphate buffer, pH 11.5, 2.5 mM DTT, 18% (w/v) glycerol, 0.05% (w/v) bromophenol blue, 
and loaded onto a 9% polyacrylamide gel (16.5 cm x 14.5 cm x 0.75 mm) made in 50 mM 
Na2HPO4, pH 11.5 with 5 M KOH. The gel was run in the same pH 11.5 buffer at 4 ºC for 5 h 
30 m, with power limited to 3W. Proteins were transferred onto a nitrocellulose membrane, 
stained with Ponceau S, and protein bands were excised from the wet membrane and 
distained in water. Proteins were eluted from the membrane slices by incubation in Laemmli 
sample buffer (50 mM Tris-HCl, pH 8.8, 2% (w/v) SDS, 0.017% (w/v) bromophenol blue, 10% 
(v/v) glycerol, 2 mM EDTA-NaOH, pH 8.0, 100 mM DTT) for 30 min at 37 ºC followed by 
incubation at 65 ºC for 30 min, and analyzed by SDS-PAGE/Coomassie blue staining, as 
described before (71). 
 
16. Blot-overlay assay 
Endogenous rat liver PEX5 was detected in western-blots by blot-overlay using 35S-
PEX14 as described before (153). The nitrocellulose membrane was incubated in renaturing 
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 100 mM potassium acetate, 5 mM MgCl2, 100 
µM ZnCl2, 1 mM DTT, 1 mM EDTA, 0.3% (w/v) Tween-20, 100 mM methionine, 5% (w/v) 
nonfat dry milk) for 2 h at 4 ºC, and probed with 35S-PEX14 (25 µL of RRL in 25 mL of 
renaturing buffer). Following incubation overnight at 4 oC, the membrane was washed twice 
with renaturing buffer, dried and exposed to an x-ray film. 
 
17. Antibodies 
Antibodies directed to catalase (RDI-CATALASEabr, Research Diagnostics, Inc.), 
KDEL (ab12223, Abcam), cytochrome c (556433, BD PharmingenTM), SCPx (19182-1-AP, 
ProteinTechTM), and Tetra-his (34670, Qiagen) were purchased. The antibody directed to 
PEX14 was described before (81). The antibody directed to PEX13 was prepared by Doctor 
Tânia Francisco. Antibodies were detected using goat alkaline phosphatase-conjugated anti-
rabbit or anti-mouse antibodies (A9919 and A2429, respectively, Sigma). 
 
18. Determination of molar ratios of DTM-bound PEX5 molecules 
For reasons that will become apparent below (see section IV-2.2.), the distribution of 
methionine residues at the N-terminus of PEX5 (see Figure 4A) had to be considered for the 
determination of molar ratios of radiolabeled DTM-bound PEX5 molecules. Also, since these 
experiments demanded quantitative autoradiography data, a storage phosphor screen and a 
Storm 860 Phosphorimager instrument (GE Healthcare) were used. According to the 
manufacturer, the captured information is proportional to the radioactivity in the sample. 
Thus, both weak and strong signals can be visualized and quantitated in a single exposure. 
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The densitometric analysis of radiolabeled protein bands in the phosphor images was 
performed with the ImageQuant® version 5.0 software (GE Healthcare). Bands were 
surrounded by rectangles (see Figure 4B), and for each selected rectangle, a single volume 
value (the volume under the surface created by a 3D plot of the pixel locations and pixel 
intensities) was determined. Volume quantitation was performed with the local median 
background correction (the middle value of all the pixel values in the rectangle outline was 
used for the background). Volume values for PEX5(C11A) were multiplied by three, as only 
one third of the in vitro reactions were loaded onto the gels. For both PEX5(1-197;C11A) and 
PEX5(1-324;C11A), the contribution of each individual band was determined. Intersecting 
lines were drawn (see Figure 4C), and the respective intensity profiles were plotted (see 
Figure 4D). The intensity profiles were then deconvoluted with the Fityk – curve fitting and 
data analysis software ((222); see Figure 4E). Then, the signal intensities of the PEX5 
species were normalized for the number of methionines (proteins were synthesized in vitro 
using 35S-methionine). To estimate ratios of binding sites at saturation for PEX5(1-
324;C11A):PEX5(C11A) and PEX5(1-197;C11A):PEX5(C11A), data from four technical 
replicates were fitted to a dose response one-site specific binding curve equation, y = Bmax * 
x / (EC50 + x), using Prism® version 7.03 software (GraphPad software). In this equation y is 
the methionine- and PNS protein-normalized autoradiography signal of PK-resistant protein 
bands, x is the volume of RRL containing the radiolabeled protein, Bmax is the maximal 
response at infinite volume of RRL, and EC50 is the volume of RRL yielding a half-maximal 
response. Note that since the actual concentrations of radiolabeled proteins in the RRL are 
not known, the absolute EC50 and Bmax values have no meaning per se. However, Bmax 
ratios provide the relative binding stoichiometries of the different PEX5 species. 
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Figure 4. Determination of molar ratios of DTM-bound PEX5 molecules. A, N-terminal sequence of the 
histidine-tagged PEX5 molecules used in this study. The conserved cysteine at position 11 is marked, as are all 
methionine residues (bold, underlined). The cleavage site of Genenase I (Gen. I ) and the approximate 
cleavage site of PK (PK ) that yields the smallest PK-resistant stage 2 PEX5 species are also shown. Note that 
there is some uncertainty in defining the latter cleavage site. Thus, two possibilities were considered: PK cleaves 
after methionine 18 or PK cleaves before methionine 18. The number of methionine residues in both intact protein 
and smallest PK-resistant PEX5 species are presented in the table on the right side. B-E, quantitative analysis of 
the phosphor images. For the densitometric analysis of radiolabeled protein bands (B), for each selected 
rectangle, a single volume value was determined, with a local median background correction. Volume values for 
PEX5(C11A) were multiplied by three, as only one third of the in vitro reactions were loaded onto the gels. To 
determine the contribution of each individual band, for both PEX5(1-197;C11A) and PEX5(1-324;C11A), 
intersecting lines were drawn (C), and the respective intensity profiles were plotted (D). The intensity profiles were 
then deconvoluted (E); the thin grey line represents the raw data obtained for the intensity profile; the black line 
represents the assisted fitting of each peak (peaks I to V); the blue lines represent the deconvoluted peaks. D and 
E, exemplified for the lane marked with an arrow in panel C. 
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1. PEX5 as a holdase-like protein 
Recently, our group proposed that PEX5 functions as a holdase-like protein. The data 
behind this concept comes from the finding that PEX5 binds monomers of human catalase (a 
tetrameric protein in its native state) and monomers of mouse ACOX and UOX (dimeric and 
tetrameric proteins, respectively), strongly inhibiting their oligomerization (107, 132). 
Additional characterization of the interaction established between PEX5 and catalase 
showed that this inhibitory effect requires more than the interaction between the PTS1 and 
the TPRs of PEX5. Indeed, the N-terminal domain of PEX5 alone presents the ability to 
inhibit catalase tetramerization, although to a lesser extent than the full-length protein (107). 
Furthermore, evidence that the N-terminal half of PEX5 contributes to the interaction 
between PEX5 and some PTS1-containing and PTS-less cargo proteins was already 
available (104–106). Thus, it seems that the natively unfolded N-terminal domain of PEX5 
embraces the newly synthesized cargo proteins in the cytosol, possibly keeping them in a 
molten-globule state (in contrast to their oligomeric forms, monomeric catalase, ACOX and 
UOX are all extremely susceptible to proteases), avoiding premature specific interactions, 
such as oligomerization prior to peroxisomal import, or unspecific interactions like unwanted 
adsorption to membrane structures (107, 132). 
To better characterize the role of PEX5 as a holdase-like protein, several strategies 
were used in this study. In one of the more classical approaches, the capacity of the N-
terminal domain of PEX5 to prevent the thermal-induced in vitro aggregation of malate 
dehydrogenase (MDH) and citrate synthase (CS) was analyzed. These two proteins are 
frequently used as model substrates for molecular chaperones since at T ≥ 43 ºC, both MDH 
and CS become unfolded and have a tendency to aggregate (216, 217). When a protein 
becomes unfolded, unspecific hydrophobic interactions occur resulting in protein 
aggregation. This aggregation is accompanied by an increase in absorbance due to light 
scattering. Molecular chaperones can bind unfolded proteins and avoid the aggregation 
process (223). It is of note that the N-terminal domain of PEX5 (specifically, a histidine-
tagged recombinant protein comprising the first 324 amino acid residues of PEX5 (PEX5(1-
324)) can be used in these assays because it remains in solution even at much higher 
temperatures, a property derived from its natively unfolded nature (140). 
 
1.1. Thermal-induced aggregation of malate dehydrogenase 
For the thermal-induced aggregation assays, MDH was incubated at 43 ºC and its 
aggregation was monitored by measuring the increase in absorbance at 340 nm (see Figure 
5, solid line). When MDH was incubated in the presence of recombinant PEX5(1-324), its 
thermal-induced aggregation was considerably decelerated (see Figure 5, dash line). On the 
contrary, BSA, used here as a negative control, had no or almost no effect in the aggregation 
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of MDH (see Figure 5, dash dot line). Thus, the N-terminal domain of PEX5 has the ability to 
prevent the thermal-induced aggregation of MDH. 
 
 
Figure 5. Effect of PEX5(1-324) on the thermal-induced aggregation of malate dehydrogenase. MDH was 
incubated at 43 ºC in the absence (solid line) or presence of either PEX5(1-324) (dash line) or BSA (dash dot 
line). Protein aggregation was followed by measuring the absorbance at 340 nm during 5400 seconds (90 min). 
Three independent experiments are shown for each condition. 
 
1.2. Thermal-induced inactivation of citrate synthase 
CS is a mitochondrial dimeric protein that catalyzes the condensation of oxaloacetic 
acid and acetyl-CoA to yield citrate and coenzyme A. CS is inactivated when incubated at 
high temperatures, and its inactivation can be easily observed by measuring the remaining 
activity of the enzyme. The reaction catalyzed by CS can be easily followed using the 
Ellman’s Reagent, which reacts with -SH groups (present in the coenzyme A that is 
produced) and gives an intense yellow color that can be measured at 412 nm (217). 
The results in Figure 6 show that the CS activity rapidly decreased when the protein 
was incubated at 44 ºC (circles). Indeed, a more than 60% decrease in activity was achieved 
after only 5 min of incubation. In the presence of recombinant PEX5(1-324), the thermal-
induced inactivation of CS was significantly delayed (see Figure 6, triangles), and after 5 and 
10 min of incubation at 44 ºC, CS retained around 70% and 50% of its initial activity, 
respectively. Incubation in the presence of BSA did have a little protective effect on the 
inactivation of CS (see Figure 6, squares), but to a considerable lesser extent than the one 
observed for PEX5(1-324). The results obtained demonstrate that the N-terminal half of 
PEX5 has the capacity to prevent the thermal-induced inactivation of CS, suggesting that 
PEX5(1-324) can interact transiently with CS or unfolding intermediates of CS. 
 
. 
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Figure 6. Effect of PEX5(1-324) on the thermal-induced inactivation of citrate synthase. CS was incubated 
at 44 ºC in the absence (circles) or presence of either PEX5(1-324) (triangles) or BSA (squares). Enzyme activity 
was measured at several time points, and is given as percentage of the zero-time value. Data points represent 
the average and standard deviation of the values obtained in four independent experiments. 
 
1.3. The effect of PEX5 on the structure of a de novo synthesized peroxisomal matrix 
protein 
The monomeric forms of catalase, ACOX and UOX are all soluble proteins displaying 
hydrodynamic properties compatible with a globular conformation (107, 132). Yet, all three 
monomers are extremely sensitive to proteolysis suggesting that they are molten-globules. 
Interestingly, their sensitivity to proteases is not altered upon binding PEX5 ((107, 132, 224), 
unpublished results), a finding that could suggest that PEX5 interacts with proteins in the 
molten-globule state. We wondered whether this might also be true for natively monomeric 
PTS1-containing proteins. A positive answer for this question would have great mechanistic 
implications because it would suggest that the best substrates for the PIM are (flexible) 
molten-globule proteins. We used luciferase as a test substrate, an enzyme that catalyzes a 
bioluminescent reaction and a protein that is actually a monomeric PTS1-containing 
peroxisomal matrix protein (88). The PEX5 capacity to bind luciferase nascent polypeptide 
chains and slow down the acquisition of their native structure, keeping them in a molten-
globule state, was tested. Briefly, using a cell-free transcription/translation system, luciferase 
was synthesized de novo and the acquisition of tertiary structure by luciferase, resulting into 
an enzymatically active conformation, was continuously monitored through the measurement 
of the light produced during the oxidation of luciferin. In vitro synthesis was performed in the 
presence of recombinant human PEX5, PEX5(N526K) (a PEX5 protein with the mutation 
N526K that greatly abrogates its PTS1-binding activity), PEX5 plus a PTS1-containing 
peptide (“SKL”), or PEX5 plus a negative control peptide (“LKS”). As shown in Figure 7, 
irrespective of whether or not PEX5 was capable or available to bind newly synthesized 
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luciferase, no differences were observed in the initial time of its activity. Thus, PEX5 did not 
show the ability to keep luciferase in a molten-globule/enzymatically inactive state. 
 
 
Figure 7. Effect of PEX5 on newly synthesized luciferase activity. A, luciferase was synthesized in vitro, at 25 
ºC, in the presence of PEX5, PEX5(N526K), PEX5 and a PTS1-containing peptide (“SKL”), or PEX5 and a control 
peptide (“LKS”), as indicated. The accumulation of active luciferase during synthesis was followed by measuring 
the light produced by luciferin oxidation. B, the same transcription/translation reactions were incubated at 25 ºC in 
a thermomixer and, during synthesis, at the indicated time points, aliquots were withdrawn and analyzed by SDS-
PAGE/autoradiography. The autoradiograph (upper panel) and the corresponding Ponceau S-stained membrane 
(lower panel) are shown. Numbers to the left indicate the molecular weight (kDa) of protein standards. 
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2. Probing the architecture of the peroxisomal matrix protein translocon using 
truncated PEX5 molecules 
 
2.1. The PEX5-PEX14 interaction is resistant to alkaline pH 
When PEX5 becomes inserted into the DTM, it acquires a transmembrane topology 
(211). Strikingly, this peroxisome-associated PEX5 population cannot be extracted from the 
membrane by alkaline pH solutions (78, 99, 211, 225), a property commonly attributed to 
integral membrane proteins that directly interact with the lipid bilayer. This biochemical 
behavior of peroxisomal PEX5 is intriguing. Although the N-terminal domain of PEX5 is 
essential and sufficient for its insertion into the peroxisomal membrane (it contains the DTM-
binding domains; (119, 150)), it does not contain any obvious phylogenetically conserved 
hydrophobic or amphipathic region that might sustain a direct interaction of PEX5 with the 
lipid bilayer of the peroxisomal membrane. In fact, the recombinant protein comprising only 
the natively unfolded N-terminal half of PEX5 is completely soluble and, even after boiling, 
displays no tendency to aggregate or precipitate (140). Even with this contradiction, the 
striking alkaline pH resistance of peroxisome-associated PEX5 has been interpreted by 
some authors as meaning that the protein directly interacts with the lipid bilayer of the 
organelle membrane and acts as a pore-forming protein (212, 226). A simpler explanation for 
the peculiar biochemical behavior of peroxisomal PEX5 is that the protein-protein interactions 
established between PEX5 on one side and the DTM components on the other may be 
resistant to alkaline pH. 
The N-terminal domain of PEX5 interacts with two DTM components, PEX13 (138, 
145, 227) and PEX14 (142–146), respectively. While the PEX5-PEX13 interaction is 
relatively weak and difficult to capture in in vitro binding assays (138, 145, 228, 229), PEX5 
interacts very strongly with PEX14 (79, 81, 142, 143, 211). Indeed, each of the eight 
pentapeptide motifs present in the N-terminal half of PEX5 bind to the first 80 amino acid 
residues of PEX14 (142, 143, 146), a conserved domain that is probably embedded in the 
peroxisomal membrane or even exposed into the organelle matrix (153, 230). Thus, we 
focused on the PEX5-PEX14 interaction. 
Two different approaches were used to determine whether or not the PEX5-PEX14 
interaction is resistant to alkaline pH. In the first, recombinant PEX5, a protein containing the 
first 80 amino acid residues of PEX14 (hereafter mentioned to as NDPEX14), as well as a 
mixture of both proteins, were subjected to pH 11.5 polyacrylamide gel electrophoresis 
(PAGE). As shown in Figure 8A and B (left panel), for the mixture of both PEX5 and 
NDPEX14 proteins (see Figure 8A, lane 2), a partial disappearance of the bands 
corresponding to the individual proteins and the presence of a new band, displaying a slower 
electrophoretic mobility, corresponding to the PEX5-NDPEX14 complex (see Figure 8B (left 
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panel), lane b) can be observed. Exactly the same results were obtained when PEX5 was 
replaced in this experiment by a protein comprising only its N-terminal half, PEX5(1-324) 
(see Figure 8A and B (right panel)). 
In the second approach, the same recombinant proteins were subjected to size-
exclusion chromatography performed in the presence of 0.1 M sodium carbonate, the 
solution generally used to extract soluble and peripheral membrane proteins from biological 
membranes (231). As shown in Figure 8C, protein complexes between PEX5 and NDPEX14 
were easily detected in the presence of 0.1 M sodium carbonate (compare panel 2 with 
panels 1 and 5). Again, the same results were obtained when PEX5 was replaced by 
PEX5(1-324) (compare panel 4 with panels 3 and 5). Clearly, the PEX5-PEX14 protein is 
stable at alkaline pH. 
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Figure 8. For figure legend, see next page. 
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Figure 8. The PEX5-PEX14 interaction is resistant to alkaline pH. A, recombinant NDPEX14 (lanes 1 and 6), 
PEX5 (lane 3), PEX5(1-324) (lane 4), a mixture of NDPEX14 and PEX5 (lane 2) or PEX5(1-324) (lane 5), were 
subjected to PAGE under alkaline conditions (50 mM phosphate buffer, pH 11.5), blotted onto a nitrocellulose 
membrane and stained with Ponceau S. B, bands marked (in A) from “a” to “c”, and from “d” to “f”, were excised 
from the membrane, the proteins were eluted with Laemmli sample buffer and analyzed by SDS-
PAGE/Coomassie blue staining (left and right panel, respectively). C, recombinant PEX5 (panel 1), PEX5(1-324) 
(panel 3), NDPEX14 (panel 5), and a mixture of NDPEX14 and PEX5 (panel 2) or PEX5(1-324) (panel 4), were 
subjected to size-exclusion chromatography under alkaline conditions (0.1 M sodium carbonate). The void volume 
of the column was in fraction 14. Fractions were collected and analyzed by SDS-PAGE/Coomassie blue staining. 
In B and C, numbers to the left indicate the molecular weight (kDa) of protein standards. 
 
Thus, there is no need to assume that the resistance of peroxisome-associated PEX5 
to alkaline extraction reflects an interaction of the protein with the lipid bilayer of the 
organelle. The striking biochemical behavior of DTM-embedded PEX5 can now be fully 
explained by the properties of the PEX5-PEX14 interaction. 
 
2.2. The DTM can accommodate more molecules of a truncated PEX5 species than 
full-length PEX5 
According to our model, the soluble receptor-cargo complex is recruited into a 
proteinaceous pore/channel formed by DTM components. However, our knowledge on the 
mechanistic principles of the PIM, i.e., on how the PIM accepts their substrates, is still very 
incomplete. The fact that PEX5 and DTM components are very low abundant proteins, even 
in peroxisome-rich cells, together with the lability of detergent-solubilized PEX5-DTM 
complex during typical biochemical procedures have complicated the structural 
characterization of the peroxisomal matrix protein translocon (79, 81). Nevertheless, indirect 
approaches such as in vitro binding analyses can still provide valuable data on the 
architecture/mechanism of protein complexes (232). In this work, we started to apply such a 
strategy to study the PEX5-DTM complex. 
The peroxisomal matrix protein import pathway has been studied in our laboratory 
using a cell-free organelle-based in vitro system (see (87)). Concisely, a 35S-labeled reporter 
protein is incubated with a rat liver post-nuclear supernatant (PNS), used as a source of 
peroxisomes and cytosolic components. Then, the organelle suspension is treated with a 
large amount of an aggressive and non-specific protease. While the radiolabeled reporter 
protein that became associated with peroxisomes is preserved, because is not accessible to 
protease, the protein that is not associated with the organelles is degraded by the protease. 
Since this is an open experimental system, different components can be added or removed 
and different strategies can be used to block the peroxisomal matrix protein import pathway 
at different and specific steps (see Figure 2). 
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In this study, cell-free PNS-based in vitro assays programmed with several 35S-
labeled PEX5 proteins were used to characterize the architecture of the peroxisomal matrix 
protein translocon. Proteinase K (PK) was used to evaluate insertion of 35S-labeled PEX5 
proteins into the peroxisomal membrane (see Figure 9). As previously mentioned, 
peroxisome-associated PEX5 displays a transmembrane topology, exposing most of its 
polypeptide chain into the organelle matrix, and only a small 2-kDa fragment of its N-
terminus into the cytosol. This population of PEX5, the so-called stage 2, is mainly 
inaccessible to protease, and after digestion with PK only the 2-kDa fragment is degraded 
(151). During its transient passage through the peroxisomal membrane, PEX5 is 
monoubiquitinated at a conserved cysteine residue (Cys11 in humans). This population of 
PEX5, the so-called stage 3, is also protease-protected, but, in contrast to stage 2 PEX5, it is 
completely resistant to digestion with PK, probably because the ubiquitin moiety or even the 
REM protects Ub-PEX5 from PK (147, 151). 
 
 
Figure 9. PK as a tool to assess the insertion of PEX5 into the peroxisomal membrane in PNS-based in 
vitro assays. Both stage 2 and stage 3 PEX5 are resistant to PK-treatment. But, while stage 2 PEX5 is partially 
accessible and the small fragment of its N-terminus that is exposed into the cytosol is cleaved by PK, stage 3 
PEX5 is completely resistant to PK. Possibly the ubiquitin moiety (or even the REM) protects Ub-PEX5 from the 
PK. Soluble PEX5 is extremely sensitive to PK-treatment and is completely degraded by the protease. 
Abbreviations used: cyt, cytosol; mat, peroxisomal matrix; TPRs, tetratricopeptide repeats domain of PEX5; PK, 
proteinase K; Ub, ubiquitin; DTM, docking/translocation module. 
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Initially, we asked whether or not full-length PEX5 and shorter, C-terminally truncated, 
versions of PEX5 can interact with the peroxisomal membrane with the same stoichiometry. 
To ensure the saturation of PEX5-binding sites at the peroxisomal membrane, mutant PEX5 
proteins, all with the cysteine at position 11 replaced by an alanine (C11A), were used in 
these experiments. This C11A mutation results in the accumulation of PEX5 into the DTM 
because the alanine residue cannot be ubiquitinated, and thus, PEX5 is not dislocated back 
into the cytosol (180). In addition to full-length PEX5 (PEX5(C11A)), two different C-
terminally truncated PEX5 proteins were used in these experiments, that is, PEX5(1-
324;C11A) and PEX5(1-197;C11A), comprising the first 324 and 197 amino acid residues of 
PEX5, respectively (see Figure 10A). All proteins were synthesized in vitro from pET-28-
derived plasmids because the synthesis yields from these plasmids were significantly larger 
than those achieved with pGEM-4-derived plasmids, used in previous works. Consequently, 
all 35S-labeled PEX5 proteins have a histidine tag at their N-termini (see Figure 10B). 
 
 
Figure 10. PEX5 molecules used in this study. A, full-length and truncated versions of the large isoform of 
human PEX5 are schematically represented. The conserved cysteine residue at position 11 (black), which was 
replaced by an alanine or a lysine in many of the proteins used in this study, the eight pentapeptide motifs 
responsible for the interaction with PEX13 and PEX14 (numbered from 0 to 7, purple bars) and the structured C-
terminal half comprising seven tetratricopeptide repeats (TPRs, green box) are indicated. B, N-terminal sequence 
of the histidine-tagged PEX5 proteins used in this study. 
 
The in vitro assays were performed at 37 ºC in the presence of ATP. Under these 
conditions, peroxisome-associated endogenous PEX5 is exported back into the soluble 
fraction of PNS, being the occupation of DTMs by the endogenous PEX5 largely decreased 
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(see Figure 11, compare lanes 2 and 4). Therefore, almost all the DTMs in the PNS are 
available to bind the 35S-labeled PEX5 protein. 
 
 
Figure 11. The amount of organelle-associated PK-protected endogenous PEX5 is largely decreased upon 
incubation at 37 ºC in the presence of ATP. A rat liver PNS in ATP-containing import buffer was incubated at 0 
or 37 ºC in the absence (lanes 1, 2 and 4) or presence (lane 3) of 10 µM recombinant NDPEX14. After incubation, 
samples were treated (+) or not (–) with PK, as indicated. Organelles were then isolated and subjected to 
reducing SDS-PAGE/western-blotting. Endogenous rat PEX5 was detected by blot-overlay using 
35
S-PEX14. 
Stage 2 and stage 3, DTM-embedded non-ubiquitinated and monoubiquitinated PEX5 species, respectively. Note 
that the Ub-PEX5 thioester conjugate is destroyed under reducing conditions. Thus, only the full-length PEX5 
protein is detected in reducing gels (147). The autoradiograph (upper panel) and the corresponding Ponceau S-
stained membrane (lower panel) are shown. Numbers to the left indicate the molecular weight (kDa) of protein 
standards. 
 
The results in Figure 12 show that saturation or near-saturation conditions were 
reached for many of the PK-resistant species detected in these assays (a densitometric 
analysis of the data is shown below). 
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Figure 12. The DTM can accommodate more PEX5(1-197;C11A) molecules than full-length PEX5(C11A). A, 
increasing volumes of rabbit reticulocyte lysates (RRL; volumes in μL indicated at the top of each lane) containing 
either PEX5(1-324;C11A) or PEX5(C11A) were used in PNS-based in vitro reactions (“rx”) performed at 37 ºC in 
the presence of ATP for 45 min. Organelle suspensions were then treated with PK, organelles were isolated and 
analyzed by SDS-PAGE/storage phosphor screen autoradiography. Total organelle samples (PEX5(1-324;C11A)) 
or one third of them (PEX5(C11A)) were loaded onto the gel. The phosphor image (upper panel), and a section of 
the corresponding Coomassie blue-stained gel (lower panel) are shown. Numbers to the left indicate the 
molecular weight (kDa) of protein standards. B, exactly as in A but using PEX5(1-197;C11A) and PEX5(C11A). In 
A and B, lanes In, RRL containing the indicated 
35
S-labeled protein. Brackets and arrow heads indicate the PK-
cleaved and intact 
35
S-labeled proteins, respectively. 
 
To confirm that the saturation observed reflects the occupation of PEX5-binding sites 
at the peroxisomal membrane, and not the titration of some soluble factor in the PNS, the 
import-competence of organelles pre-incubated with wild-type PEX5 or PEX5(C11A) was 
compared. While PEX5 cycles between peroxisomes and the soluble fraction of PNS, the 
C11A mutant accumulates into the DTM. As shown in Figure 13, the amount of PK-resistant 
PEX5(1-197;C11A) observed in organelles pre-incubated with PEX5(C11A) is lower than that 
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observed in organelles pre-incubated with PEX5. So, the saturation conditions observed in 
Figure 12 reflect occupation of PEX5-binding sites at the peroxisomal membrane. 
 
 
Figure 13. The import-competence of organelles pre-incubated with PEX5(C11A) is largely decreased. 
PEX5 and PEX5(C11A) were subjected to a PNS-based in vitro assay in the presence of ATP. After 30 min at 37 
ºC, both reactions received PEX5(1-197;C11A) and were further incubated for 10 min at 37 ºC. After PK 
treatment, organelles were isolated by centrifugation and analyzed by SDS-PAGE/autoradiography. The RRLs 
containing radiolabeled PEX5(1-197;C11A) (lane InPEX5(1-197;C11A), input of lanes 1 and 2), wild-type PEX5 (lane 
InPEX5; input of lane 1) and PEX5(C11A) (lane InPEX5(C11A); input of lane 2) were also analyzed. The autoradiograph 
(upper panel) and a portion of the Ponceau S-stained membrane (lower panel) are shown. Numbers to the left 
indicate the molecular weight (kDa) of protein standards. 
 
Interestingly, for both PEX5(1-324;C11A) and PEX5(1-197;C11A), the PK-resistant 
species exhibited an unexpected heterogeneity; besides a set of partially cleaved species, a 
protein band corresponding to intact protein was also detected (indicated with brackets and 
arrow heads, respectively, in Figure 12), particularly in the PEX5(1-197;C11A) assays. 
In order to know if all the partially cleaved species correspond to membrane-
embedded molecules exposing their N-termini into the cytosol, i.e., if all represent stage 2 
PEX5, PK-treated organelles from an in vitro assay programmed with radiolabeled PEX5(1-
197;C11A) were solubilized with detergent and digested with Genenase I. Genenase I is a 
protease that cleaves PEX5 only once near its N-terminus ((151); see also section IV-2.5.). 
As shown in Figure 14A, the PK-resistant PEX5(1-197;C11A) species were converted, by 
Genenase I, into a single 31-kDa protein, which co-migrates with the smallest PEX5(1-
197;C11A) fragment generated by PK (compare lanes 3 and 4). Thus, all the partially 
cleaved species detected for PEX5(1-197;C11A) correspond to stage 2 PEX5. 
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Figure 14. Characterization of PK-resistant, partially cleaved, PEX5(1-197;C11A) species. A, RRL 
containing PEX5(1-197;C11A) (lanes 1 and 2) or PK-treated organelles (Org.) from a PNS-based in vitro assay 
programmed with PEX5(1-197;C11A) (lanes 3 and 4) were incubated (+) or not (–) with Genenase I (G I) for 30 
min at 23 ºC, as indicated. Samples were analyzed by SDS-PAGE/autoradiography. Autoradiograph (upper 
panel) and the corresponding Ponceau S-stained membrane (lower panel) are shown. Bracket and arrow head 
indicate the PK-cleaved and intact 
35
S-labeled proteins, respectively. B, recombinant histidine-tagged PEX5(1-
197;C11A) was incubated in the absence (–) or presence (+) of Genenase I (G I) for 3 h 30 min at 23 ºC, as 
indicated. Samples were analyzed by SDS-PAGE/Coomassie blue staining. The “<” symbol indicates Genenase I. 
In A and B, numbers to the left indicate the molecular weight (kDa) of protein standards. 
 
The heterogeneity of the peroxisomal PK-cleaved PEX5 species observed for the C-
terminally truncated versions of PEX5 (see Figure 12), together with the distribution of 
methionine residues at the N-terminus of PEX5 (see Figure 4A), raises some uncertainty in 
the determination of stoichiometries of DTM-bound PEX5 molecules. Thus, three different 
possibilities were considered (see Figure 15A). The most likely possibility (scenario #1) 
assumes, for the C-terminally truncated versions of PEX5, that: 1) the smallest PK-resistant 
PEX5 species (peak I, see also Figure 4E) has the same size, and therefore the same 
number of methionines, of Genenase I-cleaved PEX5 species (see Figure 14A); 2) the 
largest PK-cleaved PEX5 species (peak IV, see also Figure 4E) is larger than the 
corresponding untagged PEX5 species (see below); and 3) the difference in size between 
any two adjacent PK-resistant species in the SDS-gel is approximately 1 kDa (see Figure 
12). The other two possibilities assume that: 1) band/peak IV is larger than the untagged 
protein (see below); and 2) all the other PK-cleaved species contain either the minimum 
(scenario #2) or the maximum (scenario #3) number of possible methionines. 
The results of these analyses are shown in Figure 15B. Considering the most likely 
distribution of PK-cleavage sites in the PEX5 molecules (scenario #1), at saturation 
conditions, the estimated molar ratios of DTM-bound PEX5(1-197;C11A), PEX5(1-
324;C11A), and PEX5(C11A) were 2.5:1.2:1, respectively. The other two possibilities 
assume PK-cleavage sites that result in the largest (scenario #2) and smallest (scenario #3) 
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molar ratios of DTM-bound PEX5(1-197;C11A):PEX5(1-324;C11A):PEX5(C11A) – estimated 
values of 3.2:1.4:1 and 1.8:1:1 were obtained, respectively. Thus, the results clearly indicate 
that the DTM can accommodate more PEX5(1-197;C11A) molecules than full-length 
PEX5(C11A). In fact, these ratios are probably larger because intact PK-resistant PEX5(1-
197;C11A) is also specifically bound to peroxisomes, as shown below. 
 
 
Figure 15. Molar ratios of DTM-bound PEX5(1-324;C11A) or PEX5(1-197;C11A) to PEX5(C11A), 
considering three different scenarios. A, different possibilities (scenario #1, #2 and #3) for the distribution of 
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PK-cleavage sites in the N-termini of truncated versions of PEX5, that results in peaks I to IV (see Figure 4). B, 
molar ratios of DTM-bound PEX5(1-324;C11A) or PEX5(1-197;C11A) to PEX5(C11A). Averages and standard 
deviations from four replicates are shown. Signal intensities from the quantitative analysis of the phosphor images 
were normalized for protein loads and for the methionine number in each radiolabeled protein, fitted to a dose 
response one-site specific binding curve, and divided by the Bmax value obtained for full-length PEX5(C11A). In 
scenario #1, Bmax values for PEX5(1-197;C11A) and PEX5(C11A) are 2.52 (95% confidence interval (CI) = 1.82-
4.46) and 1.00 (95% CI = 0.90-1.11), respectively (left panel); and Bmax values for PEX5(1-324;C11A) and 
PEX5(C11A) are 1.21 (95% CI = 0.88-1.99) and 1.00 (95% CI = 0.85-1.18), respectively (right panel). In scenario 
#2, Bmax values for PEX5(1-197;C11A) and PEX5(C11A) are 3.24 (95% CI = 2.32-5.87) and 1.00 (95% CI = 
0.90-1.11), respectively (left panel); and Bmax values for PEX5(1-324;C11A) and PEX5(C11A) are 1.35 (95% CI 
= 0.97-2.28) and 1.00 (95% CI = 0.85-1.18), respectively (right panel). In scenario #3, Bmax values for PEX5(1-
197;C11A) and PEX5(C11A) are 1.82 (95% CI = 1.31-3.24) and 1.00 (95% CI = 0.90-1.11), respectively (left 
panel); and Bmax values for PEX5(1-324;C11A) and PEX5(C11A) are 1.02 (95% CI = 0.75-1.69) and 1.00 (95% 
CI = 0.85-1.18), respectively (right panel). Note that intact PEX5(1-324;C11A) and intact PEX5(1-197;C11A) data 
cannot be fitted to the same dose response curve (“ambiguous fit”); in these cases the lines simply connect 
averages. Note that the abscissa scale is different for the two radiolabeled proteins. Note also that for some 
points the error bars are shorter than the height of the symbols. 
 
2.2.1. Characterization of intact PK-resistant PEX5(1-197;C11A) species  
The existence of a PK-resistant species corresponding to intact protein in the 
saturation binding experiments described above was particularly striking. These assays were 
performed with non-ubiquitinatable PEX5 molecules and, to date, only DTM-embedded Ub-
PEX5 (stage 3) was known to display this behavior. Thus, the properties of this species were 
analyzed in detail. 
Since unusual large amounts of radiolabeled proteins were used in these assays, the 
possibility of intact PK-resistant species might be a consequence of some non-specific event 
(e.g., encapsulation of a small fraction of the radiolabeled protein into some membrane 
vesicles during sample processing) was considered. In order to know if the intact PK-
resistant species is localized at the peroxisomes, a PK-treated PNS-based in vitro reaction 
programmed with radiolabeled PEX5(1-197;C11A) was loaded onto the top of a Histodenz™ 
step gradient and centrifuged. Twelve fractions were collected from the bottom of the 
gradient and subjected to SDS-PAGE/western-blotting/autoradiography (see Figure 16A). 
This method takes advantage of the high density of peroxisomes compared with the other 
organelles present in the PNS (233). The distribution of mitochondria and endoplasmic 
reticulum was assessed with antibodies directed to cytochrome c and the retention signal 
KDEL, respectively; both were found in fractions 7-12. Only peroxisomes were found near 
the bottom of the gradient, as assessed using an antibody directed to PEX14. Importantly, 
intact PK-resistant PEX5(1-197;C11A) co-purified with peroxisomes, as did stage 2 PEX5(1-
197;C11A). Moreover, as shown in Figure 16B, intact PK-resistant PEX5(1-197;C11A) was 
not extracted from the peroxisomal membrane by sonication in a low ionic-strength buffer, 
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similarly to stage 2 species. Under these conditions, the peroxisomal matrix protein catalase 
was released and found in the soluble fraction, as expected. Therefore, intact PK-resistant 
PEX5(1-197;C11A) represents a peroxisome membrane-bound species.  
To evaluate the specificity of its association with peroxisomes, radiolabeled PEX5(1-
197;C11A) was subjected to a PNS-based in vitro reaction in the presence of NDPEX14. As 
previously mentioned, the N-terminal domain of PEX14 binds with high affinity to the 
pentapeptide motifs present in the N-terminal half of PEX5 (142, 143, 146), and as a result, 
blocks the insertion of the receptor into the peroxisomal membrane (87, 152). As shown in 
Figure 16C, no PK-resistant species were detected in this assay, indicating that the 
association of intact PK-resistant PEX5(1-197;C11A) with peroxisomes is as specific as that 
yielding stage 2 PEX5(1-197;C11A). 
 
 
Figure 16. Characterization of intact PK-resistant PEX5(1-197;C11A) species. A, a PK-treated PNS-based in 
vitro reaction performed with PEX5(1-197;C11A) was loaded onto the top of a Histodenz™ gradient and 
centrifuged. Twelve fractions were then collected from the bottom of the gradient and analyzed by SDS-
PAGE/western-blotting/autoradiography. An autoradiograph (upper panel) showing the distribution of PK-resistant 
PEX5(1-197;C11A) species, and western-blots probed with antibodies directed to PEX14 (peroxisomes), 
cytochrome c (cyt c; mitochondria) and the retention signal KDEL (endoplasmic reticulum) are presented. Note 
that PEX14 is converted into a small fragment upon PK digestion (153). B, PK-treated organelles from an in vitro 
assay programmed with PEX5(1-197;C11A) were disrupted by sonication. Half of the sample was kept on ice 
(lane T), and the other was centrifuged to separate membrane (lane P) and soluble (lane S) fractions. Samples 
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were analyzed by SDS-PAGE/western-blotting/autoradiography. The autoradiograph (upper panel) showing PK-
resistant PEX5(1-197;C11A) species, and blots showing the distribution of catalase (a peroxisomal matrix protein) 
and PEX14 (an intrinsic membrane protein) are presented. C, PEX5(1-197;C11A) was subjected to a PNS-based 
in vitro assay in the absence (lane 1) or presence (lane 2) of 10 µM recombinant NDPEX14. PK-treated 
organelles were analyzed by SDS-PAGE/autoradiography. The autoradiograph (upper panel) and the 
corresponding Ponceau S-stained membrane (lower panel) are shown. In B and C, lanes In, RRL containing 
35
S-
labeled PEX5(1-197;C11A). In A to C, brackets and arrow heads indicate the PK-cleaved and intact 
35
S-labeled 
PEX5(1-197;C11A), respectively. Numbers to the left indicate the molecular weight (kDa) of protein standards. 
 
Furthermore, the amount of intact PK-resistant PEX5(1-197;C11A) was largely 
decreased when the in vitro assays were performed in the presence of recombinant full-
length PEX5(C11A) (see Figure 17, compare lanes 4 and 5). Conversely, recombinant 
PEX5(1-197;C11A) prevented the insertion of PEX5(C11A) into the peroxisomal membrane 
(compare lanes 7 and 8). Taken together, the results strongly suggest that both truncated 
and full-length PEX5 molecules compete for the same PEX5-binding sites at the organelle 
membrane. 
 
 
Figure 17. PEX5(1-197;C11A) and PEX5(C11A) compete for the same PEX5-binding sites at the 
peroxisomal membrane. PNS in import buffer containing ATP was pre-incubated for 5 min at 37 ºC in the 
absence (–) or presence (+) of the indicated recombinant proteins (15 μg each of PEX5(1-197;C11A), or 
PEX5(C11A), or TPRs). Radiolabeled PEX5(1-197;C11A) and PEX5(C11A) were then added, as specified, and 
the reactions were incubated for 30 min. PK-treated organelles were then subjected to SDS-PAGE/ 
autoradiography. The autoradiograph (upper panel) and a portion of the Ponceau S-stained membrane (lower 
panel) are shown. Lanes In, RRL containing radiolabeled PEX5(1-197;C11A) and PEX5(C11A), as indicated. 
Stage 2 PEX5(1-197;C11A) (bracket) and intact PK-resistant PEX5(1-197;C11A) (arrow head) are also indicated. 
Numbers to the left indicate the molecular weight (kDa) of protein standards. 
 
As stated above, all the PEX5 molecules used in these assays have a histidine tag at 
their N-termini. For full-length PEX5(C11A), the histidine tag does not change its behavior 
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during PK digestion; essentially all the peroxisome-associated PEX5(C11A) was degraded 
by PK into a slightly shorter protein (see Figure 12), as observed before for the untagged 
PEX5 (e.g., see figure 1 in (147)). To determine whether or not the unexpected heterogeneity 
observed for the peroxisome-associated C-terminally truncated versions of PEX5, upon PK 
digestion, results from the presence of the histidine tag in an artificially truncated PEX5 
protein, a very large volume of an in vitro synthesized untagged version of PEX5(1-
197;C11A) was used in an in vitro assay. Similar PK-resistant species were detected with the 
untagged protein (see Figure 18, compare lanes 2 and 3). Seemingly, intact PK-resistant 
species are observed in these assays as a result of the large amount of C-terminally 
truncated PEX5 molecules used in the in vitro reactions. 
 
 
Figure 18. PEX5(1-197;C11A) without a N-terminal histidine tag behaves similarly to PEX5(1-197;C11A) in 
PNS-based in vitro assays. RRL (16 μL) containing untagged PEX5(1-197;C11A) was used in a PNS-based in 
vitro assay, the reaction was divided into two halves (lanes 3 and 4) and one half was treated with PK, as 
indicated. For comparison, an identical assay performed with the histidine-tagged PEX5(1-197;C11A) (lanes 1 
and 2) is also shown. Organelle pellets were then subjected to SDS-PAGE/autoradiography. The autoradiograph 
(upper panel) and a portion of the Ponceau S-stained membrane (lower panel) are shown. Lanes In, RRL 
containing 
35
S-labeled histidine-tagged or untagged PEX5(1-197;C11A). Stage 2 (bracket) and intact PK-resistant 
(arrow head) species from histidine-tagged PEX5(1-197;C11A) are indicated. Numbers to the left indicate the 
molecular weight (kDa) of protein standards. 
 
To better understand the nature of the intact PK-resistant PEX5(1-197;C11A), the 
radiolabeled protein was subjected to a PNS-based in vitro reaction, aliquots were taken at 
different time points, and digested with PK. The isolated organelles were analyzed by SDS-
PAGE/storage phosphor screen autoradiography. As shown in Figure 19, the intact PK-
resistant species displays a slower kinetics than partially cleaved species. Apparently, the 
PEX5-binding site occupied by this abnormal PEX5 population is kinetically different from the 
one occupied by the partially cleaved species. The saturation-binding experiments presented 
in Figure 12B might already suggest this. 
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Figure 19. Peroxisome-membrane binding kinetics of intact PK-resistant PEX5(1-197;C11A). RRL 
containing PEX5(1-197;C11A) was incubated with a PNS in import buffer containing ATP. At the indicated time 
points, aliquots were withdrawn, treated with PK and the organelles were isolated and analyzed by SDS-
PAGE/storage phosphor screen autoradiography. The brackets and arrow heads indicate PK-cleaved and intact 
PK-resistant PEX5(1-197;C11A), respectively. An intensity profile of each lane is shown. 
 
In summary, the results obtained suggest that PEX5(1-197;C11A) and PEX5(C11A) 
bind to the same PEX5-binding sites at the peroxisomal membrane, but interact with the 
DTM with different stoichiometries. Seemingly, many of the sites available to bind a full-
length PEX5(C11A) molecule can accommodate more than one truncated PEX5(1-
197;C11A) molecule. 
 
2.3. DTM-bound PEX5(1-125;C11A/K) is accessible to PK 
When radiolabeled PEX5(1-125;C11A) – a protein comprising only the first 125 amino 
acid residues of PEX5 (see Figure 10A) – is subjected to a PNS-based in vitro assay, PK-
resistant species are not observed (see Figure 20, compare lanes 3 and 4 with lanes 7 and 
8). In principle, this might suggest that the protein is not associated with the peroxisomes. 
However, when radiolabeled PEX5(1-125;C11K) – a protein also comprising only the first 
125 amino acid residues of PEX5 but with a lysine at position 11 (C11K) – is incubated with a 
primed PNS in the presence of AMP-PNP (a non-hydrolysable ATP analog that can be used 
by the ubiquitin-conjugating cascade but not by the REM, (86)), and the PK treatment is 
omitted, a monoubiquitinated species is clearly detected (see Figure 20, compare lanes 1 
and 5). Also, Ub-PEX5(1-125;C11K) is accessible to PK (see Figure 20, compare lanes 1 
and 2 with lanes 5 and 6), similarly to PEX5(1-125;C11A). Thus, the protein comprising the 
first 125 amino acid residues of PEX5 associates with the peroxisome, and is a substrate for 
the DTM RING finger peroxins, but remains accessible to PK. 
Note that the replacement of the cysteine 11 by a lysine results in a functional PEX5 
protein that behaves as the wild-type both in in vitro and in in vivo assays, i.e., it is inserted 
into the DTM, monoubiquitinated and extracted to the cytosol in an efficient manner (180). 
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However, while the thioester bond between ubiquitin and the cysteine from PEX5 wild-type is 
quite labile and tends to hydrolyze during non-reducing SDS-PAGE, the isopeptidic bond 
linking ubiquitin to PEX5(C11K) species is not. Therefore, the use of C11K mutants is 
experimentally advantageous because SDS-PAGE can be done under reducing conditions. 
 
 
Figure 20. PEX5(1-125;C11K) is correctly monoubiquitinated but does not acquire a PK-protected status. 
A primed PNS was used in AMP-PNP-supplemented in vitro assays programmed with PEX5(1-197;C11K) (lanes 
1 and 2; “C11K”), or PEX5(1-197;C11A) (lanes 3 and 4; “C11A”), or PEX5(1-125;C11K) (lanes 5 and 6; “C11K”), 
or PEX5(1-125;C11A) (lanes 7 and 8; “C11A”). One half of each reaction was treated with PK, as indicated. 
Organelle fractions were analyzed by SDS-PAGE/western-blotting/autoradiography. The autoradiograph (upper 
panel) and the corresponding nitrocellulose membrane probed with an antibody directed to SCPx (lower panel), to 
assess intactness of peroxisomes (224), are shown. The exposure time of the PEX5(1-125;C11K/A) panel was 4-
fold larger than the one of PEX5(1-197;C11K/A) to obtain identical intensities of the ubiquitinated species. Note 
that PEX5(1-197;C11K/A) and PEX5(1-125;C11K/A) have the same number of methionines. Lanes InK and InA, 
RRL containing the C11K and C11A versions of the indicated 
35
S-labeled proteins, respectively. Numbers to the 
left indicate the molecular weight (kDa) of protein standards. 
 
The interaction between PEX5 and the DTM happens in two steps: a reversible 
docking, in which PEX5 remains at the organelle surface and protease-accessible (152), 
followed by the irreversible (in the absence of ATP) insertion of PEX5 into the DTM, where 
PEX5 remains protease-resistant (151). One possible explanation for the results presented in 
Figure 20 is that PEX5(1-125;C11A/K) is unable to enter the DTM remaining trapped at the 
docking step and, therefore, PK-accessible. To test this hypothesis, organelles isolated from 
a PNS-based in vitro reaction performed with radiolabeled PEX5(1-125;C11K) in the 
presence of AMP-PNP were resuspended in import buffer and incubated with either 
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recombinant PEX5(1-324) or PEX19. PEX5(1-324) interacts with the DTM and competes 
with PEX5 at the docking step (152), whereas PEX19 is a protein involved in a different 
aspect of peroxisomal biogenesis and was used here as a negative control (66). Organelle-
associated proteins and soluble proteins were then separated by centrifugation and 
subjected to SDS-PAGE/autoradiography. Because protease-treatment cannot be done in 
this type of experiments, the radiolabeled protein that remains non-specifically adsorbed to 
the organelles is not degraded, explaining the relatively large background observed (see 
(152)). As shown in Figure 21, a fraction of the non-ubiquitinated PEX5(1-125;C11K) was 
specifically extracted from the organelles upon incubation with recombinant PEX5(1-324), 
indicating that the protein was specifically adsorbed to peroxisomes, as expected for a PEX5 
molecule at the docking step (152). On the contrary, all the Ub-PEX5(1-125;C11K) remained 
in the organelle pellet upon incubation with recombinant PEX5(1-324). Seemingly, Ub-
PEX5(1-125;C11K) is beyond the docking step. 
 
 
Figure 21. Ub-PEX5(1-125;C11K), but not PEX5(1-125;C11K), is tightly bound to organelles. PEX5(1-
125;C11K) was incubated with a primed PNS in AMP-PNP-containing import buffer for 30 min. The organelles 
were then recovered by centrifugation, resuspended in import buffer and divided into three tubes. One tube was 
kept on ice (lane T), and the other two were incubated for 15 min at 37 ºC in the presence of 10 μg of either 
recombinant PEX5(1-324) or PEX19, as indicated. Organelles (P) and the corresponding supernatants (S) were 
separated by centrifugation and analyzed by SDS-PAGE/autoradiography. The autoradiograph (upper panel) and 
a portion of the corresponding Ponceau S-stained membrane (lower panel) are shown. Lane In, RRL containing 
the 
35
S-labeled PEX5(1-125;C11K). The a and b indicate monoubiquitinated and non-ubiquitinated PEX5 species, 
respectively. Numbers to the left indicate the molecular weight (kDa) of protein standards. 
 
We next subjected PEX5(1-125;C11K) to a two-step import-export experiment (86), 
aiming at determining whether this truncated PEX5 species is also a substrate for the REM. 
Succinctly, radiolabeled PEX5(1-125;C11K) was incubated with a primed PNS in the 
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presence of AMP-PNP (to accumulate Ub-PEX5(1-125;C11K) at the DTM), then the isolated 
organelles were resuspended in import buffer and incubated with either AMP-PNP (to 
maintain the block of the REM) or ATP (to activate the REM). Organelle-associated and 
soluble proteins were analyzed by SDS-PAGE/western-blotting/autoradiography. As shown 
in Figure 22 (right panel), in the export reaction containing AMP-PNP, Ub-PEX5(1-125;C11K) 
remained in the organelle fraction, as expected. In the ATP-containing export reaction, on the 
contrary, a large fraction of Ub-PEX5(1-125;C11K) was released into the supernatant. The 
same results were obtained with PEX5(1-197;C11K), used here as a positive control (Figure 
22 (left panel)). Thus, Ub-PEX5(1-125;C11K) is a substrate for the REM. Similar results had 
been previously observed in our laboratory for the untagged version of this protein (215). 
 
 
Figure 22. Ub-PEX5(1-125;C11K) is a substrate for the REM. PEX5(1-197;C11K) (left panels) or PEX5(1-
125;C11K) (right panels) were incubated with a primed PNS in import buffer supplemented with ubiquitin 
aldehyde and AMP-PNP. The reactions were then centrifuged to separate supernatant fraction (Si) from 
organelles (Pi). The organelles were resuspended in an ATP- or AMP-PNP-containing import buffer, and further 
incubated for 15 min at 37 ºC. The organelle suspensions were again centrifuged to obtain a supernatant (Se) 
and an organelle pellet (Pe). Samples were analyzed by SDS-PAGE/western-blotting/autoradiography. The 
autoradiographs (upper panels) and the behavior of endogenous PEX13 (lower panels) are shown. Si, equivalent 
to 50 μg of PNS; Pi, Pe and Se, equivalent to 600 μg of PNS. Lanes In, RRL containing radiolabeled PEX5(1-
197;C11K) and PEX5(1-125;C11K), as indicated. The a and b indicate monoubiquitinated and non-ubiquitinated 
PEX5 species, respectively. Numbers to the left indicate the molecular weight (kDa) of protein standards. 
 
As previously mentioned, DTM-embedded PEX5 displays a transmembrane topology, 
exposing most of its polypeptide chain into the peroxisomal matrix (211). To determine 
whether or not PEX5(1-125;C11K) also acquires a transmembrane topology during its 
passage through the DTM, we employed a strategy previously used to show that a portion of 
the polypeptide chains of PEX5 and PEX7 reach the peroxisomal matrix (186, 214). 
Specifically, two almost identical PEX5(1-125;C11K) proteins, both having at their C-termini 
an extension of about 5 kDa, were synthesized. In one of these proteins, called PEX5(1-
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125;C11K)-clv, the extension comprises a cleavable, but otherwise non-functional, PTS2 
derived from pre-thiolase pre-sequence (214), followed by 19 amino acid residues 
corresponding to the N-terminus of human sterol carrier protein-2; the other protein, named 
PEX5(1-125;C11K)-nclv, is identical to PEX5(1-125;C11K)-clv with the exception that it lacks 
the last two residues of the non-functional pre-thiolase pre-sequence (see Experimental 
Procedures for details). This deletion was designed based on the observation that a similar 
deletion in pre-phytanoyl CoA hydroxylase dramatically decreased its processing efficiency 
at the peroxisomal matrix (116). The PTS2-containing proteins are processed upon import, in 
the peroxisomal matrix, by Tysnd1 (97). Thus, if the C-terminus of PEX5(1-125;C11K)-clv 
becomes exposed into the peroxisomal matrix, a 2-kDa shorter protein should be generated 
by the action of Tysnd1. In contrast, no or very little cleavage should be observed for 
PEX5(1-125;C11K)-nclv. 
Both radiolabeled proteins were subjected to PNS-based in vitro assays performed in 
the presence of AMP-PNP, and organelle-bound and soluble proteins were analyzed by 
SDS-PAGE/autoradiography. The results in Figure 23 show that a small fraction of PEX5(1-
125;C11K)-clv was converted into a smaller protein (indicated by an arrow head). Thus, at 
least a fraction of PEX5(1-125;C11K)-clv acquires a transmembrane topology during its 
transient passage through the DTM. 
 
 
Figure 23. PEX5(1-125;C11K)-clv is partially processed in the PNS-based in vitro assay. PEX5(1-
125;C11K)-clv and PEX5(1-125;C11K)-nclv were subjected to PNS-based in vitro assays in the presence of AMP-
PNP for 60 min. The reactions were then centrifuged to separate organelles (lanes P) from soluble proteins (lanes 
S). Organelles and soluble fractions from 600 μg and 100 μg of PNS, respectively, were subjected to SDS-PAGE/ 
autoradiography. Lanes Inclv and Innclv, RRL containing the indicated 
35
S-labeled proteins. The autoradiograph 
(upper panel) and the corresponding Ponceau S-stained membrane (lower panel) are shown. The cleaved 
species is indicated by an arrow head. Numbers to the left indicate the molecular weight (kDa) of protein 
standards. 
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In summary, the results obtained suggest that a small protein containing only the first 
125 amino acid residues of PEX5 can enter the DTM, yielding a correct substrate for the 
RING finger peroxins and for the REM, and yet remains largely accessible to PK added from 
the cytosolic side of the peroxisomal membrane. 
 
2.4. Two non-overlapping PEX5 fragments interact with the DTM in a competitive 
manner 
In addition to the PEX5 molecules previously mentioned, a N-terminal truncated 
molecule comprising the amino acid residues 138 to 639 of PEX5 (PEX5(ΔN137)) was used 
in this study (see Figure 10A). It was already shown that PEX5(ΔN137) can still become 
inserted into the DTM in a cargo-dependent manner (215). Importantly, this protein shows no 
sequence overlap with PEX5(1-125). 
To determine whether or not both PEX5(ΔN137) and PEX5(1-125) compete for 
insertion into the DTM, PNS-based in vitro assays were programmed with radiolabeled 
PEX5(1-125;C11K) in the presence of AMP-PNP and recombinant PEX5(ΔN137) or TPRs. 
TPRs lack the PEX5 domain required for a productive interaction with the DTM and was 
used as a negative control. Organelles were then isolated and analyzed by SDS-
PAGE/autoradiography. The results in Figure 24 show that the amount of Ub-PEX5(1-
125;C11K) was largely decreased when PEX5(ΔN137) was added to the reaction (lanes 4-
6). The same result was observed for PEX5(1-197;C11K) (lanes 1-3), a protein that shares 
some DTM-interacting regions with PEX5(ΔN137) (see Figure 10A). So, the two proteins 
compete for insertion into the DTM. 
 
 
Figure 24. Two non-overlapping PEX5 fragments interact with the DTM in a competitive manner. PEX5(1-
197;C11K) and PEX5(1-125;C11K) were subjected to PNS-based in vitro assays in the presence of AMP-PNP 
and in the absence (–) or presence (+) of 1 µM of recombinant PEX5(ΔN137) or TPRs, as indicated. Organelle 
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fractions were analyzed by SDS-PAGE/autoradiography. The autoradiograph (upper panel) and a portion of the 
corresponding Ponceau S-stained membrane (lower panel) are shown. The exposure time of the PEX5(1-
125;C11K) panel was 4-fold larger than that of PEX5(1-197;C11K). Lanes In, RRL containing the indicated 
35
S-
labeled proteins. The a and b indicate monoubiquitinated and non-ubiquitinated PEX5 species, respectively. 
Numbers to the left indicate the molecular weight (kDa) of protein standards. 
 
To clarify if the competition between PEX5(ΔN137) and PEX5(1-125;C11K) is 
occurring at the docking step or only at the insertion step, the experiment presented in Figure 
21 was repeated but this time using recombinant PEX5(ΔN137) as a competitor of organelle-
associated PEX5(1-125;C11K). As shown in Figure 25, a fraction of the non-ubiquitinated 
PEX5(1-125;C11K) was specifically extracted from the organelles upon incubation with 
recombinant PEX5(ΔN137), suggesting that PEX5(ΔN137) competes with PEX5(1-
125;C11K) at the docking step. 
 
 
Figure 25. PEX5(ΔN137) competes with PEX5(1-125;C11K) at the docking step. PEX5(1-125;C11K) was 
incubated with a primed PNS in AMP-PNP-containing import buffer for 30 min. The organelles were then isolated 
by centrifugation, resuspended in import buffer and divided into three tubes. One tube remained on ice (lane T). 
The others were incubated for 15 min at 37 ºC in the presence 10 µg of either recombinant PEX5(ΔN137) or 
TPRs, as indicated. Organelle (P) and soluble proteins (S) were separated by centrifugation and analyzed by 
SDS-PAGE/autoradiography. The autoradiograph (upper panel) and a portion of the corresponding Ponceau S-
stained membrane (lower panel) are shown. Lane In, RRL containing 
35
S-labeled PEX5(1-125;C11K). The a and 
b indicate monoubiquitinated and non-ubiquitinated PEX5 species, respectively. Numbers to the left indicate the 
molecular weight (kDa) of protein standards. 
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2.5. Supplemental results – Mapping of the Genenase I-cleavage site in PEX5 
Genenase I is an engineered protease, a variant of the subtilisin from Bacillus 
amyloliquefaciens, in which the catalytic histidine was replaced by an alanine. This protease 
works by “substrate-assisted catalysis”: a histidine from the substrate substitutes the mutated 
catalytic residue and contributes to the catalysis (220). It is described that Genenase I 
cleaves particularly well at sites possessing a histidine at the P2 position and a 
phenylalanine or a tyrosine at the P1 position (220). Two such sequences exist in human 
PEX5 – His23Phe24 and His578Phe579 – but previous work suggests that only the first is 
cleaved by Genenase I (151). To confirm the exact cleavage site of Genenase I in PEX5, 
intact and Genenase I-cleaved recombinant histidine-tagged PEX5(1-197;C11A) (see Figure 
14B) were analyzed by mass spectrometry in the reflectron mode at i3S Proteomics Core 
Facility. Note that residues His23Phe24 of human PEX5 correspond to residues His43Phe44 
of the histidine-tagged PEX5(1-197;C11A). For the intact protein, no small peptides were 
found (see Figure 26A), while for the Genenase I-cleaved protein, five major small peptides 
were detected (see Figure 26B). Importantly, all map to the 1-44 amino acid region of 
histidine-tagged PEX5(1-197;C11A) (see Figure 26C). 
The same protein samples were also analyzed by mass spectrometry in the linear 
mode. Masses of 23963.6 Da (MH+) for the intact protein (theoretical mass 23961.172 Da 
(MH+), excluding the initial methionine) and 19405.6 Da for the Genenase I-cleaved protein 
were determined (see Figure 27A and B). This suggests that Genenase I removes a region 
of 4576 Da from PEX5(1-197;C11A), in good agreement with the theoretical molecular mass 
of 4576.13 Da for a peptide comprising amino acid residues 2-44 of the protein. Collectively, 
the results from mass spectrometry show that Genenase I cleaves PEX5 immediately after 
Phe24. 
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Figure 26. Mass spectrometry analyses of intact and Genenase I-cleaved recombinant histidine-tagged 
PEX5(1-197;C11A) in the reflectron positive mode. A, intact histidine-tagged PEX5(1-197;C11A). B, Genenase 
I-cleaved histidine-tagged PEX5(1-197;C11A). Arrows indicate the internal standards added to the sample. C, 
FindPept software (221) output for the five major peptides observed in the panel B (“unspecific cleavage” option 
and mass tolerance of 10 ppm). 
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Figure 27. Mass spectrometry analyses of intact and Genenase I-cleaved recombinant histidine-tagged 
PEX5(1-197;C11A) in the linear positive mode.  A, intact histidine-tagged PEX5(1-197;C11A). B, Genenase I-
cleaved histidine-tagged PEX5(1-197;C11A). In A and B, the arrow indicates the internal mass standard horse 
myoglobin. 
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PEX5 is essential for the peroxisome biogenesis, as it is involved in all stages of the 
peroxisomal matrix protein import pathway. Our group proposed that PEX5, in addition to a 
receptor and translocator for peroxisomal matrix proteins, is also a holdase-like protein that 
binds its newly synthesized cargo proteins into the cytosol, preventing premature or incorrect 
interactions (107). In this study, several strategies were used to explore the role of PEX5 as 
a holdase-like protein. The thermal-induced aggregation of malate dehydrogenase and 
inactivation of citrate synthase were both prevented by the N-terminal half of PEX5, 
suggesting that PEX5 can act as a holdase-like protein. 
As already mentioned, the monomeric versions of catalase, ACOX and UOX, display 
hydrodynamic properties compatible with a globular conformation. However, in contrast to 
the corresponding oligomeric native forms, these monomeric proteins are extremely sensitive 
to proteases. Interestingly, this protease-sensitivity is maintained when they interact with 
PEX5, suggesting that PTS1-containing molten globules are the bona fide substrates of the 
PIM. If true, then even peroxisomal proteins that are monomeric in their native state might be 
kept in a molten globule conformation by PEX5, prior to the import step. This mechanism 
was appealing to us for two reasons: 1) it would provide a simple way to maintain newly 
synthesized peroxisomal matrix proteins in an inactive state during their transit through the 
cytosol, thus avoiding undesirable reactions in the cytosol (e.g., the generation of H2O2); 2) it 
would suggest that, although fully folded and even oligomeric proteins can be substrates for 
the PIM, this machinery might function even better with molten globule substrates, which are 
much more flexible than already folded proteins. To test this hypothesis, we asked whether 
the presence of recombinant human PEX5 during the in vitro synthesis of firefly luciferase 
would block/retard the folding of this enzyme. Unfortunately, the results were negative. Thus, 
either the initial hypothesis is wrong (i.e., the PIM does not discriminate between folded 
monomeric proteins and monomeric molten globules), or this phenomenon is difficult to 
capture in vitro. The fact that PEX5 proteins from human and insect are rather different 
(particularly at their N-terminal half) might also explain this negative result. Thus, it is clear 
that additional work has to be done to clarify this issue. 
The ability to accept already folded proteins as substrates is not an exclusive property 
of the peroxisomal matrix protein import machinery. In fact, in both eukaryotes and 
prokaryotes, several protein transport systems have this capacity. Examples include the 
nuclear pore complex, some bacterial secretion systems, the twin-arginine translocation 
system, and the pore-forming proteins. Although these protein transport systems present an 
overwhelming diversity of compositions and architectures, they can be coarsely grouped into 
three mechanistic classes. First, those that comprise a gated pore of fixed composition and 
geometry that enables the transport of folded and soluble cargo proteins across a membrane 
(e.g. the nuclear pore complex and the bacterial type II and IV secretion systems (234–236)). 
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Second, those that comprise membrane proteins with the ability to assemble into an 
appropriately sized transient channel every time a cargo protein has to be transported (i.e., 
the Tat system (237)). Finally, those where initially soluble proteins undergo oligomerization 
and major conformational changes enabling them to insert into a membrane creating pores 
of variable dimensions (pore-forming proteins (238)). An important question in the field of 
peroxisome biogenesis is which of these three mechanisms, if any, best describes the PIM. 
Several years ago our research group proposed that newly synthesized folded matrix 
proteins are translocated through the peroxisomal membrane by PEX5 itself, when PEX5 
becomes inserted into the DTM (151, 161, 211). This model postulates that the soluble 
receptor-cargo complex is recruited into a gated proteinaceous pore/channel formed by DTM 
components. The striking resistance of peroxisome-associated PEX5 to alkaline extraction 
(211), has been interpreted within the context of all the other PEX5 data (151), as probably 
meaning that there is some unusually strong protein-protein interaction involving PEX5 and 
components of the DTM (99, 166, 211, 225). 
A different perspective is presented in the “transient pore model”, which uses the 
alkaline-resistance of peroxisomal PEX5 as its main supporting fact (212). We note that, in 
its essence, this model is a derivative of the one described above, i.e., it also proposes that 
cargo proteins are pushed through the peroxisomal membrane by PEX5 itself, when the 
receptor interacts with the DTM. However, it introduces the novelty that the protein 
translocation pore is formed by a combination of PEX5 molecules and DTM components 
(e.g., PEX14), all of them interacting directly with the lipid bilayer of the peroxisomal 
membrane, and all together creating the hydrophilic pore that allows the translocation of 
cargo proteins through the membrane (212, 213). 
The results obtained in this study show that in the absence of membrane lipids the 
PEX5-PEX14 interaction is resistant to alkaline pH and, thus, clarify the discrepancies 
between the biochemical behavior of DTM-embedded PEX5 and the primary structure and 
biochemical properties of the N-terminal domain of PEX5, which were never entirely 
explained by the transient pore model. Clearly, there is no need to assume that PEX5 is a 
pore-forming protein because alkaline-resistance of peroxisomal PEX5 has now a much 
simpler explanation – the PEX5-PEX14 is alkaline-resistant.  
Although additional biochemical work and detailed structural data will be necessary to 
understand the mechanism and architecture of the PIM, the results obtained in this study 
with the PEX5 truncated molecules can be used to infer some of its properties. 
Interestingly, the saturation-binding experiments revealed that PEX5(C11A) and 
PEX5(1-197;C11A) interact with the peroxisomal membrane with different stoichiometries 
(see Figure 28). Apparently, several of the sites available to bind a single full-length 
PEX5(C11A) protein can accommodate more than one truncated PEX5(1-197;C11A) protein. 
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This finding suggests that each site at the DTM that is occupied by a single full-length PEX5 
protein comprises more than one PEX5-interacting domain. Moreover, at least some of these 
PEX5-interacting domains are most likely equivalent, i.e., they can bind to the same PEX5 
sequence(s). 
 
 
Figure 28. Model of the peroxisomal matrix protein translocon (DTM). The DTM, comprising the 
transmembrane proteins PEX14, PEX13 and RING finger PEX2, PEX10 and PEX12, is a large cavity-forming 
protein assembly into which soluble PEX5 enters to release its cargo. Each site at the DTM available to bind one 
full-length PEX5 molecule can accommodate one PEX5(1-324) molecule or 2-3 PEX5(1-197) molecules (thick 
arrows). The small PEX5(1-125) species also interacts correctly with DTM, albeit with low efficiency (dashed 
arrow); interestingly, it remains largely accessible to proteinase K added from the cytosolic side of the membrane. 
Furthermore, PEX5(ΔN137) competes with PEX5(1-125) in the interaction with the DTM (red line), a finding 
suggesting that the DTM can recruit cytosolic PEX5 through different pentapeptide motifs. The putative disorder 
of DTM components (purple ovals with wavy lines) might contribute to this interaction flexibility. The C-shaped 
form and the thick blue line represent the PTS1-binding domain and the intrinsically disordered N-terminal half of 
PEX5, respectively. The black dots indicate the pentapeptide motifs involved in the interactions with PEX14 and 
PEX13. 
 
The finding that PEX5(ΔN137) competes with PEX5(1-125;C11K) for insertion into 
the DTM is also interesting. Currently, we do not know if this competition is due to steric 
hindrance or if the two proteins bind the same DTM component(s). However, the fact that two 
PEX5 proteins showing no sequence overlap can enter into the DTM suggests that this 
complex can interact with PEX5 using alternative binding paths. In other words, during the 
docking and insertion steps, it is possible that the initial interactions that occur between a 
single PEX5 protein and the DTM, most of them probably involving PEX14 (107, 156), do not 
necessarily involve a well-defined order of events. If true, this would suggest that at least 
some of the interactions established between PEX5 and the DTM are polymorphic, and most 
likely better described by the principles that rule fuzzy protein-protein interactions (see (239, 
 76 
 
240)). The data discussed above for PEX5(1-197), the fact that the N-terminal half of PEX5 
is a natively unfolded domain interacting with DTM components mainly (if not exclusively) 
through several small motifs, together with an abundance of intrinsic disorder in many DTM 
components, such as PEX13 and PEX14 (see Figure 29), are surely compatible with this 
idea. 
 
 
Figure 29. In silico prediction of PEX13 and PEX14 disorder using the Predictor of Natural Disordered 
Regions (PONDR®)-VLXT algorithm (241). About 40% and 60% of human PEX13 and PEX14 sequences, 
respectively, are predicted to be intrinsically disordered. 
 
The results showing that PEX5(1-125;C11K) is a correct substrate for the RING finger 
peroxins and for the REM indicate that the amino acid residues 126 to 639 of PEX5 do not 
contain crucial information to the ubiquitination and export components of the PIM. 
Importantly, peroxisome-associated PEX5(1-125;C11K) is largely accessible to PK added 
from the cytosolic side of the peroxisomal membrane. This might suggest that PEX5(1-
125;C11K) remains trapped at the docking step and that docking is enough to position this 
PEX5 molecule in the correct orientation to be monoubiquitinated at the DTM and exported 
by the REM. However, the interaction of Ub-PEX5(1-125;C11K) with the DTM is irreversible, 
contrary to the PEX5-DTM interaction at the docking step. Moreover, at least a fraction of 
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PEX5(1-125;C11K)-clv acquires a transmembrane topology and exposes its C-terminus into 
the peroxisomal matrix. So, it is more likely that PEX5(1-125) becomes inserted into the 
DTM, as all the other PEX5 proteins used in this study do, but that due to its small size there 
is still sufficient space inside the DTM to provide access to PK. 
In summary, the data presented in this study reveal novel aspects of the PEX5-DTM 
interaction and provide additional evidence to support the idea that the DTM comprises the 
transmembrane hydrophilic channel in which soluble PEX5 enters to deliver its cargoes into 
the peroxisomal matrix. 
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